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Keratinocytes represent the major cell type in the skin. During cutaneous leishmaniasis (CL) 
and schistosomiasis, the skin is important during the parasite life cycle. While Th1 immunity 
is required to control CL, protection during schistosomiasis requires Th2 immunity. 
Paradoxically, Th2 characteristic IL-4 secreted early during L. major infection in mice, can 
drive a Th1 response by instructing dendritic cells to produce IL-12. Additionally, 
keratinocytes at the site of L. major infection in C57BL/6 mice, were postulated to be the source 
of the IL-4. We investigated if IL-4/IL-13 signalling via the IL-4Rα on keratinocytes 
contributed to early immunity during CL and schistosomiasis. Keratinocyte-specific IL-4Rα 
deficient (KRT14creIL-4Rα-/lox) BALB/c and C57BL/6 mice were generated by gene targeting 
and site-specific recombination (cre/loxP) under control of the KRT14 locus. In the L. major 
footpad model, KRT14creIL-4Rα-/lox BALB/c mice developed increased swelling, high parasite 
burdens, and cytokine and antibody secretion similar to littermate controls. L. major-infected 
KRT14creIL-4Rα-/lox C57BL/6 mice had decreased footpad swelling, low parasite burdens, a 
dominant Th1 cytokine response, and low type 1 and 2 antibody titres, similar to littermate 
control and resistant C57BL/6. In the L major ear model, KRT14creIL-4Rα-/lox BALB/c mice 
developed increased swelling, high parasite burdens, Th1 and Th2 cytokines, and high antibody 
titres, similar to littermate controls. L. major LV39-infected KRT14creIL-4Rα-/lox BALB/c mice 
showed significantly decreased parasite burdens in the ear, compared to littermate controls. L. 
major-infected KRT14creIL-4Rα-/lox C57BL/6 mice in the ear model, had decreased swelling, 
low parasite burdens, a dominant Th1 immune response, and low type 1 and 2 antibody titres, 
similar to littermate control and C57BL/6 mice. In the Schistosoma model, survival of S. 
mansoni-infected KRT14creIL-4Rα-/lox BALB/c mice was similar to littermate controls during 
mortality studies. During acute infection, S. mansoni-infected KRT14creIL-4Rα-/lox BALB/c 
mice showed gut pathology, hepatosplenomegaly, cytokine production, low type 1 and high 
type 2 antibodies, similar to littermate controls. In comparison to littermate controls, S. 
mansoni-infected KRT14creIL-4Rα-/lox BALB/c mice had smaller granulomas. Collectively, our 
results indicate that IL-4/IL-13 signalling through the IL-4Rα on keratinocytes is not required 
for control during CL or acute schistosomiasis, but does contribute to efficient granuloma 





Chapter 1: Introduction and literature review 
1.1 The immune system 
The immune system represents the assortment of cells and proteins, collectively working 
together to protect the body and its contents from foreign, invading agents, including viruses 
and bacteria among others. Essentially, it is a mechanism of defence to successfully overcome 
pathogenic invasion. The immune system may be separated into two components: the innate 
and the adaptive immune response [1-3].  
1.1.1 Innate immunity 
The innate immune response is the first line of defence against invading pathogens. This 
response is non-specific and employed almost immediately (within minutes), or within the first 
few hours of having encountered the pathogen. There is no immunological memory, hence no 
recognition of the same pathogen during a re-exposure. The innate immune system functions 
to recruit specialised immune cells to the site of infection or inflammation [2-4]. 
The innate immune pathway includes anatomical and physiological barriers. Anatomical 
barriers comprise: the skin, which acts as mechanical barrier to protect against germs, the mucus 
membrane present in the respiratory and gastrointestinal tract to trap microorganisms, and the 
ciliary propulsion on epithelial cells in the lungs to eradicate microbes. Physiological barriers 
comprise: lysozyme secretion (including enzymes in lysozyme of tears), low pH, complement, 
antimicrobial peptides, specialised cells, and cytokines including interferons. During damage 
to tissue, an acute phase inflammatory response is elicited. The initial response causes the body 
temperature to be raised, followed by an increase in the production of various acute-phase 
proteins (C-reactive and mannan-binding proteins for e.g.), primarily by the liver. Some acute 
phase proteins bind molecules present on bacterial or fungal cell wall, through pattern 
recognition (C-reactive and serum amyloid proteins), while the mannan-binding lectin will 
bind to mannose sugar molecules not present on mammalian cells. While they are non-specific, 
acute phase proteins are responsible and important in directing phagocytic cells to the site of 
infection [1-4]. 
As mentioned above, the innate immune system comprises a range of specialised cells. 
Granulocyte cells contain densely staining granules within their cytoplasm, and includes the 
neutrophils, eosinophils, and basophils. The duration of their life span is a few days, however, 
they are produced in great numbers, in response to foreign agents. The neutrophils comprise 
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the largest group of cells, and are extremely important for the execution of the innate immune 
pathway. Neutrophils are phagocytic cells that eradicate the foreign agents by engulfing them 
and taking them into intracellular vesicles in their cytoplasm, which contain lysing enzymes 
and antimicrobial agents. Macrophages are also phagocytic cells, responsible for the killing of 
pathogens, but also being important in presenting foreign agents to the immune system [3, 4]. 
They recruit other phagocytic cells to the infection site by chemokine release. Classically 
activated macrophages or M1 macrophages, are induced by intracellular pathogens, which 
results in a nitric oxide-mediated killing inflammatory immune response. Conversely, 
alternatively activated macrophages or M2 macrophages, act in response to certain 
extracellular pathogens, and have important regulatory functions [5, 6]. Macrophages also play 
a role in allergic responses. Alveolar macrophages are found in the lung and are crucial in 
pulmonary immunity [7, 8]. 
Eosinophils and basophils are fewer in numbers when compared to neutrophils, and they 
release their enzymes and toxic proteins from their cytoplasmic granules, in response to 
invading agents, especially against parasitic agents. Basophils are non-phagocytic cells that 
release granules containing histamines, serotonin, and prostaglandins, and along with 
eosinophils and mast cells, are important in promoting allergic responses and of anti-parasitic 
immunity. Mast cells contain large granules in their cytoplasm, and upon activation, these are 
released, assisting the induction of inflammation. Eosinophils that release cytotoxic factors, are 
important for the eradication of pathogens that are too large to be phagocytosed [1-4]. 
Natural killer (NK) cells are large and also granulated, and are important in the identification 
and elimination of cells that have been infected with a virus, as well as tumor cells. They release 
cytotoxic granules, which contain cytotoxic granzymes and perforin (a pore forming protein) 
onto the target cells surface. This allows for granzymes to penetrate the cell membrane and 
trigger programmed cell death [1-4] 
Dendritic cells (DCs) have long finger-like protrusions. There are different types of dendritic 
cells. The immature dendritic cells travel from the bone marrow to tissues, via the bloodstream. 
They are phagocytic cells, taking up and degrading pathogens. This causes the dendritic cells 
to become mature cells, which by presenting the resultant antigens from pathogen degradation, 
are capable of activating the adaptive immune T lymphocytes. It is for this reason, they are 
referred to as antigen presenting cells (APCs). Due to their function as messengers between the 




1.1.2 Adaptive immunity 
The adaptive immune pathway is triggered when the innate immune pathway cannot efficiently 
eradicate the foreign invading agent, which may cause an infection to occur. Essentially, the 
principal functions of this pathway is to: 1, recognise specific “non-self” antigens in the 
presence of “self” antigens; 2, generate pathogen-specific immunologic pathways that 
eradicate the specific foreign agent or pathogen-infected cells; and 3, to develop immunologic 
memory capable of efficiently and rapidly eradicating  the specific pathogen in the event of re-
infection [3, 9]. Compared to the innate immune pathway, adaptive immunity takes time to 
develop, and has greater specificity. This pathway employs two specialized groups of cells: T 
and B lymphocytes. As mentioned above, APCs may activate T and B cells by presenting a 
variety of antigens to randomly generated and unique antigen receptors on the surface of the 
cells. On the surface of APCs, are protein molecules called major histocompatibility complex 
(MHC). Two classes of MHC exists: class I, presenting intracellular peptides on all nucleated 
cells; and class II, presenting extracellular peptides on a group of immune cells, including DCs, 
B cells and macrophages. When cells become infected with a foreign agent, the MHC will 
present the pieces of the foreign antigen. During this time, costimulatory molecules that are 
expressed on APCs will engage receptors on T cells. Upon activation of the T cell receptor 
(TCR) on T cells by the APCs MHC-peptide complex, the T cell and DCs will secrete small 
proteins called cytokines (e.g. IL-4 and IFN-γ (T cell) or IL-12, and IL-18 (DCs), among 
others) to assist in the elicited immune response [1, 3, 4, 10]. As a result of antigen presentation, 
T cells may differentiate into a number of subtypes, discussed below in Section 1.1.4. Our 
study was, however, focussed mostly on two of these types: T helper (Th) cells (cell markers: 
CD3+CD4+), important in carrying out the immune response, by guiding a variety of cells 
required to elicit the response; and cytotoxic T (Tc) cells (cell markers CD3+CD8+), whose 
main purpose is to eradicate infected cells. While Th cells are activated by MHC class II-bound 
peptides, Tc cells are activated by MHC class I-bound peptides [3, 4]. 
1.1.3 Cytokines 
Cytokines are a group of small soluble protein molecules (approximately 25 kDa) with 
pleiotropic functions, that are crucial in establishing an efficient immune response [1, 11, 12]. 
They are specialized proteins secreted by cells as a form of message or communication to other 
cells, so as to alter or affect them (paracrine), or in fact to alter or affect the secreting cell itself 
(autocrine). In order to send the intracellular signals, cytokines will bind to specific receptors 
on the surface of the cell. Cytokines do not have a very long half-life. They are produced by 
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almost every cell, and serve various purposes. Cytokines play a crucial role in numerous 
processes, including: cell activation and division; repair; apoptosis; cell differentiation and 
proliferation, among others. Different types of cytokines may be produced by different cells. 
Th1 cells secrete primarily interferon-γ (IFN-γ), IL-2, and tumor necrosis factor-β (TNF-β), 
while Th2 cells secrete primarily IL-4, IL-5, IL-6, IL-10 and IL-13 [1-4, 12, 13]. 
1.1.4 CD4+ T cell differentiation  
T cell activation and differentiation is dependent on the environment, the type or mode of APC, 
co-stimulatory molecules, and cytokine production. All T cells express the CD3- antigen 
specific receptor, and depending on the pathogen encountered and the cytokine profile, once 
activated, they may differentiate into separate and distinct effector groups. [14-18]. The Th1 
and Th2 immune pathways mentioned above are the two major classes of the T cell response, 
each class producing its unique sets of cytokines [3, 19, 20]. JAKs (janus tyrosine kinases) and 
STATs (signal-transducing activators of transcription) are families of proteins, whose 
intracellular signalling pathways may be activated by various cytokines. Differentiation to a 
Th1 pathway may be induced by the increased production of IL-12 via the STAT1/T-bet 
pathway. In a nutshell, Th1 characteristic cytokines including IFN-γ and IL-12, stimulate the 
JAK-STAT pathway, which results in the activation of certain genes. STATl and STAT4 are 
activated by innate immune cytokines during early infection, are important for the development 
of a Th1 response. STATl induces the expression of T-bet, a transcription factor, in activated 
CD4 T cells, switching on genes for the IFN-γ and the IL-12 receptor, and causing these cells 
to follow the Th1 lineage. Dendritic cells and macrophages secrete IL-12, activating STAT4, 
required for expansion and differentiation of the Th1 cells. The increased or primary production 
of the Th1 cytokines IFN-γ, IL-2 and IL-12 results from a positive feedback loop, and allows 
for the protection of the host against many intracellular pathogens. The IL-2 cytokine is 
important for cell proliferation, as well as the stimulation and cytotoxicity of CD8+ T cells. 
The Th1 response employs classically activated macrophages mentioned above, CD8+ T cells 
and natural killer cells for their cytotoxic functions, as well as protective IgG antibodies, and 
delayed-type hypersensitivity [1, 2, 21-27].  
The Th2 pathway is brought about by IL-33 secretion of epithelial cells which activates a set 
of cells known as innate lymphoid cells (ILC), more specifically, ILC2, via the T1/ST2 
receptor. The ILC2 cells respond by producing IL-4, which promotes the Th2 response via 
STAT6/GATA3 expression. Essentially, when T cell activation with antigen occurs, and it 
comes into contact with IL-4, STAT6 becomes activated by the receptor for IL-4 (IL-4Rα). 
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STAT6 is important for the expression of GATA3, a transcription factor that activates genes 
for various Th2 produced cytokines, including IL-4 and IL-13, which are associated with 
helminth, asthma and allergic responses [1-4]. Th2 cytokines also include IL-5, IL-6, and IL-
9. Th2 immunity promotes responses that are mediated by eosinophils, mast cells, and IgE 
antibodies. Essentially, a source of IL-4 may be produced by conventional T and B cells, 
basophils and eosinophils, among other cells, and this induces B cell class-switching to IgE. 
Th2 immunity also employs alternatively activated macrophages described above, mast cell 
proliferation, eosinophilic inflammation, goblet cell hyperplasia, and the production of excess 
mucous. During acute infections, there is a combined effort between both Th1 and Th2 
responses, in contrast to chronic infection or allergic reactions, where either of the two 
responses may become dominant [3-9]. Due to inhibitory intracellular effects, Th1 and Th2 
responses counter regulate each other. This is evident in the suppression of a Th2 polarised 
response by Th1-derived IL-12 and STAT1, and conversely, the prevention of Th1 cells from 
developing, by Th2-derived IL-10 and GATA-3 [19, 20].  
Other T cell subsets exist, to carry out immune functions together with Th1 and Th2 responses 
[28]. Th17 cells are induced earlier on during the adaptive immune response, with their primary 
role being reported to defend against extracellular bacteria and fungi, occurring via the 
stimulation of neutrophils. A Th17 immune response progresses when T cells secrete IL-21, 
which acts on the same cells and activates STAT3 (transcription factor) which is important for 
the Th17 response. While the presence of IL-6 and transforming growth factor beta (TGF-β) 
are required for the production of Th17 cells, also required is the absence of IL-4 and IL-12 [1, 
29-31]. TGF-β, which are Th3 lineage T cells, is important for the generation of 
CD4+CD25+FoxP3+ regulatory T cells (Treg), which are implicated in IL-10-linked immune-
suppression to avert inflammatory responses that are dangerous [32, 33]. TGF-β is also 
responsible for re-programming Th2 T helper cells to remove their IL-4 cytokine profile, and 
replace it with IL-9, converting them to Th9 lineage [34-36]. A Th5 subset of T cells that 
produce IL-5 also exists, and is dependent on the signalling of IL-33 via the ST2 and Myd88 
pathway [37, 38].  
1.1.5 Keratinocytes 
The skin is the first line barrier of protection in both humans and animals, and regarded as an 
immune organ. It contains various cells in the dermis and epidermis (stratified epithelium 
composed of 10-20 layers of keratinocytes), including dermal dendritic cells and epidermal 
Langerhans cell. The cell population, however, that comprises 90% of the cells found in the 
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epidermis, are the keratinocytes. Due to their abundance, a role for these cells in maintaining 
healthy and infection/wound-free skin should not be surprising [39].  
There are 4 types of keratinocytes, based on both phenotypic and biochemical properties: basal; 
spinous; granular; and cornified keratinocytes. The classification of basal keratinocytes is 
based on their close contact with the basement membrane, their mitotic activity, and the 
expression of keratin (K) intermediate filaments, K5 and K14 [40]. While they do also begin 
the expression of the keratins K1 and K10, the earliest markers of terminal differentiation, these 
are only expressed fully, later in the upper spinous and granular layers [41, 42]. As the 
keratinocytes move through the epidermal layers, they switch from a state of proliferation 
(growing/producing in numbers) in the basal layer, to a state of differentiation. By the time 
they reach the cornified layer, they become flattened and dead (Figure 1.1) [43-45]. 
 
 
Figure 1.1 Schematic illustration of the structure of the epidermis. Major constituent keratinocytes 
are present at various levels, and characterised by keratin (K). Basal layer keratinocytes are in close 
proximity to the basement membrane (BM) and express K5, K14 and K15. As keratinocytes 
differentiate, they form the subsequent layers: spinous and granular; which express K1 and K10, and 
the cornified layer of dead cells. Image sourced from Pastar et al. [46].  
In addition to barrier maintenance, keratinocytes are important for restoring the epidermis after 
injury during the process of epithelialization (covering shed/denuded epithelial surface). 
Wound healing is a normal biological process [47]. It involves various extracellular matrix 
components, soluble mediators, and resident cells, which include fibroblasts, nerve cells and 
keratinocytes, and subtypes of infiltrating leukocytes. All these components are involved in the 
process of wound healing, which, in early studies was characterised as a three phased process: 
inflammation; tissue formation; and tissue remodelling (Figure 1.2) [48, 49], but with further 
7 
 
research, is now characterised as a four phased process: haemostasis, inflammation, 
proliferation, and tissue remodelling/resolution (Figure 1.3) [50].   
 
 
Figure 1.2 Schematic representation illustrating stages and cells involved during wound healing. 
(A) 12-24 hours after injury: wounded area is filled with a blood clot and neutrophils have invaded into 
the clot. (B) 3-7 days after injury: majority of neutrophils have undergone apoptosis, macrophages are 
now abundant in the wound tissue, endothelial cells migrate into the clot and proliferate to form new 
blood vessels, fibroblasts migrate into the wound tissue to proliferate and deposit extracellular matrix, 
keratinocytes proliferate at the wound edge and migrate down the injured dermis and above the 
provisional matrix. (C) 1–2 weeks after injury: the wound is completely filled with granulation tissue, 
fibroblasts have transformed into myofibroblasts, leading to wound contraction and collagen deposition. 





Figure 1.3 Wound healing model time line. The four phases of the wound healing process are 
illustrated: hemostasis; inflammation; proliferation; and remodelling. Keratinocytes are important in 
the remodelling phase during epithelialization. Image sourced from Mele [52]. 
While the role of epidermal keratinocytes in the protection against injury was valued for a great 
period of time, the role they play in immunological defence only attracted attention many years 
later, when it became known and appreciated, that keratinocytes produce abundance of growth 
factors, cytokines, as well as chemo-attractants [53]. Furthermore, it has been demonstrated 
that in skin-related diseases, such atopic dermatitis and psoriasis, where keratinocytes and 
lymphocytes are involved, there is crucial signalling between these two types of cells [54]. 
Their importance in immunology is further demonstrated in conditions such as inflammatory 
reactions and wound healing, during which they respond to injury in the epidermis by becoming 
activated. In this activated state, they begin to produce and respond to growth factors and 
cytokines, they become migratory, and gain the ability to produce basement membrane 
constituents [55]. Once activated, keratinocytes will express a specific set of keratin proteins 
that is different to the keratins expressed in the healthy epidermal layer. Activated keratinocytes 
in the suprabasal layer, will not express K1and K10 as described above, but will instead 
produce K6 and K16 [56, 57]. K17 keratin has also been identified when inflammatory 
processes occur during psoriasis, which involves the infiltration of the Th1 lymphocytes [54, 
58]. Activated keratinocytes begin to produce growth factors for signalling, as well as cytokines 
such as IL-3, IL-6, and IL-8 [59, 60], which are chemotactic attractants for white blood cells 
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and paracrine (acting upon other cells) for fibroblasts, lymphocytes, and endothelial cells [61]. 
The signals are also autocrine (acting upon itself) for the keratinocytes.  
It has also been shown, that through cytokines that are either Th1- or Th2- lymphocyte derived, 
are capable of differently regulating gene expression of keratin in the epidermis [53, 54]. While 
keratinocytes produces and secrete its own set of cytokines, cytokines that are produced by 
other neighbouring epidermal or infiltrating cells, can affect and influence the production of 
keratinocyte-derived cytokines, either directly or indirectly. IL-4, IL-13 and IL-17 are a few of 
these cytokines [62-64]. Keratinocytes express the IL-4 receptor, at mRNA and protein level. 
It has also been demonstrated that treatment with IL-4 promotes the proliferation of 
keratinocytes, in addition to the production of keratinocyte-derived IL-6 [62, 63, 65]. 
Furthermore, the IL-13 receptor has also been illustrated on keratinocytes, and as with the 
treatment with IL-4, treatment with IL-13 increases the production of keratinocyte-derived IL-
6 [64, 66]. In addition to the IL-4 receptor, receptors for IL-17 are also present, and when 
activated, it mediates the effect of IFN-γ or IL-4 on the process of keratinocyte activation [62, 
67]. 
The use of mouse models have been extremely valuable in providing information about the 
functions and systemic effects with respect to cytokines and their receptors, and keratinocytes 
[68-70]. Using transgenic mice has improved our knowledge on the role of cytokines with 
respect to the epidermis, and additionally, specific keratin promoters, such as the K14 promoter 
(or KRT14cre), has provided us with vital information regarding the expression of cytokines 
targeted to the epidermal layer [71-75]. 
1.2 IL-4/IL-13  
1.2.1 IL-4 
As described above, IL-4 is extremely important for the establishment and regulation of a Th2 
immune response. The genes coding for the IL-4 cytokine in mice (14-19 kDa glycoprotein) 
are closely situated to the genes coding for IL-5, IL-13 and the granulocyte macrophage-colony 
stimulating factor (GM-CSF) [76]. IL-4 is secreted by numerous cell types including: 
conventional and γδ T cells [77-79]; mast cells [80]; basophils [81]; eosinophils [82], and 
natural killer T (NKT) cells [83], among others. IL-4 is required for growth and survival of T 
cells [1]. In B cells, IL-4 is crucial for their activation by influencing the expression of low 
affinity IgE receptor [84], as well as upregulating the expression of the activation markers 
MHCII, CD80 and CD86 [85], for promoting growth and class-switching to IgG1 and IgE in 
mice and suppressing the production of the IgM, IgG2a and IgG2b antibody classes [86, 87]. 
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In mast cells, IL-4 is required for growth [1]. IL-4 is also essential in host protective responses 
elicited against helminth infections [88-91], as well as in the pathogenesis of asthma  [92, 93] 
(Figure 1.4). While it is generally accepted that IL-4 is central for Th2 immunity, certain studies 
using mouse models, have proved otherwise, illustrating that Th2 immune responses can be 
independent of IL-4 signalling [94-97]. 
1.2.2 IL-3 
The IL-13 gene which codes for a 10-14 kDa immunoregulatory protein, is situated on 
chromosome 11, between the genes coding for IL-4 and GM-CSF genes [98, 99], with a few 
biological functions shared between IL-13 and IL-4 [100]. IL-13 is produced by various cell 
types, including T cells, DCs, mast cells, basophils, and NK cells [101-103]. IL-13 is essential 
in regulating immune responses against asthma (Figure 1.4), allergy and anaphylaxis [92, 93]. 
Additionally, IL-13 effector functions influences various cells including macrophages, B cells, 
eosinophils, fibroblasts, mast cells, and smooth muscle cells [104]. Unlike IL-4, IL-13 cannot 
act on T cells [105]. On monocytes and macrophages, IL-13 upregulates the expression of 
integrins such as CD11b and CD11c [105]. The IL-13, like IL-4, is important for proliferation 
and activation of B cells [106]. 
 
Figure 1.4 Schematic diagram of the potential cellular effects of IL-4/IL-13 on inflammatory and 
structural cells in asthma. Th2- mast cell-derived IL-4 and IL-13 promotes airway inflammation via 
the activation of eosinophils, macrophages, and dendritic cells; airway remodelling by enhancing the 
proliferation and activation of fibroblasts; IgE production by activating B cells; mucus production by 
stimulating airway epithelial cells and goblet cells; and airway hyper-responsiveness by activating 
airway smooth muscle cells. Image sourced from Oh et al. [107]. 
11 
 
1.2.3 IL-4 and IL-13 receptor complexes 
IL-4 and IL-13 share a common receptor, the IL-4 receptor alpha chain (IL-4Rα), which may 
contribute to similar functions shared between the two cytokines [11, 94, 108]. In mice, the IL-
4Rα is 785 amino acids in length, with a long cytoplasmic region consisting of 5 conserved 
tyrosine amino acid resides, suggesting that tyrosine phosphorylation may be important in IL-
4Rα function [109]. The IL-4Rα belongs to the hematopoetin receptor superfamily, a family 
important for the signalling of various cytokines as well as growth factors on hematopoietic 
cells [108]. Apart from being expressed on hematopoietic cells, IL-4Rα is also expressed on 
endothelial and epithelial cells, muscle cells, brain tissue, etc. [108].  
IL-4 signals exclusively through the heterodimer type 1 receptor, which is composed of the IL-
4Rα subunit and the common gamma chain (γc) [108, 110], with both IL-4 and IL-13 signalling 
through the type II receptor, that is composed of the IL-4Rα and IL-13-binding receptor chain 
(IL-13Rα1) subunits [108, 110]. The receptors through which IL-4 and IL-13 signalling is 
mediated, is illustrated in Figure 1.5 [107]. Binding of the cytokines to the receptors varies. 
Alone, IL-13Rα1 is bound specifically by IL-13 with low affinity, however, when the IL-
13Rα1 is combined with IL-4Rα as a unit, IL-13 binds to this with a high affinity [98, 110, 
111]. Furthermore, IL-13 will bind with a high affinity to the homodimeric IL-13Rα2, which 
for a long time was regarded as a decoy receptor fulfilling no signalling requirements, mostly 
due to the cytoplasmic domain being fairly short with no binding motifs for signalling [112]. 
Recent work has, however, demonstrated otherwise, providing evidence that IL-13Rα2 is 
indeed responsible for the induction of the TGF-β production and the mediation fibrosis in 
Crohn’s disease, during chronic disease [113-115]. These IL-13 receptors are found to be 
expressed in both haematopoietic cells (except T cells) and non-haematopoietic cells in mice 
and humans [98, 116, 117]. IL-4 and IL-13 may bind with a high affinity to soluble forms of 
IL-4Rα and IL-13Rα2, which cannot signal, and in doing so, this allows the receptors to 
competitively inhibit the two cytokines, consequently regulating the activity of the IL-4 and 




Figure 1.5 Schematic diagram of the IL-4/IL-13/STAT-6 signalling pathways. IL-4 and IL-13 
signal via the IL-4Rα, a component of the type I (IL-4Rα and γc) and type II receptors (IL-4Rα and IL-
13Rα1). IL-4 signals via both type I and II receptor pathways, while IL-13 signals only via the type II 
IL-4R. IL-13 also binds to the IL-13Rα2 chain, which does not contain a transmembrane signalling 
domain and was thought to act as a decoy receptor. γc activates JAK3, while IL-13Rα1 activates 
tyrosine kinase 2 (TYK2) and JAK2. Activated JAKs will then phosphorylate STAT-6. Phosphorylated 
STAT-6 dimerises, and migrates to the nucleus, to binds to the promoters of the IL-4 and IL-13 
responsive genes associated with Th2 cell differentiation, airway inflammation, airway hyper-
responsiveness and mucus production. Image sourced from Oh et al. [107]. 
 
1.2.4 Mechanisms of IL-4 and IL-13 signalling through the IL-4Rα chain 
Signalling of IL-4 and IL-13 through the IL-4Rα, leads to the activation of the STAT-JAK 
signalling pathway [108]. IL-4 binds to IL-4Rα which induces the activation of JAK proteins, 
and results in tyrosine phosphorylation of the IL-4Rα chain. STAT-6 then binds to the 
phosphorylated receptor, allowing for C-terminal domain phosphorylation by the activated 
kinases. Thereafter, the activated STAT-6 is released from the bond with the receptor, and via 
interaction of the phosphorylated C-terminal domain with a conserved domain, forms 
homodimer components. These STAT-6 homodimers then migrate to the nucleus, to bind to 
specific DNA motifs present in the promoter of responsive genes, resulting in enhanced 
transcription. Signalling of IL-4 via IL-4Rα has also been shown to trigger the 
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1.2.5 Cell-specific IL-4Rα 
The use of gene-deficient mice has been extremely useful in delineating the role of the IL-4Rα 
signalling molecule in protection or susceptibility of hosts to pathogen infections. Advances in 
genetics have, however, introduced a more advanced method, i.e. the Cre/loxP recombination 
system, allowing for the deletion of a gene on a specific cell-type [126-129]. In this system, a 
mouse that has been genetically modified, i.e. a transgenic mouse, carries a Cyclization 
recombinase (Cre) gene, which is under the control of a promoter that is specific for a particular 
cell-type. This transgenic mouse is mated with another transgenic mouse that has been 
modified to carry the gene of interest, and is flanked by a pair of loxP binding sites. Upon 
mating, an inter-crossing of genes occurs, and the promoter will induce the expression of the 
Cre, but only on those specific cell-types, and the enzyme carries the gene deletion via 
homologous recombination of the loxP sites. In order to achieve a deletion of IL-4Rα on a 
specific cell type, our laboratory generated a transgenic mouse that carries IL-4Rα gene exon 
7 to exon 9 that is flanked by loxP sites. Several cell specific-IL-4Rα knock-out mice have been 
generated in our laboratory. These cells include pan T cells [130], CD4+ T cells [131, 132]; B 
cells [133], macrophages [134], dendritic cells [135] neutrophils [134], and smooth muscle 
cells [136, 137]. 
 
1.3 Leishmaniasis  
1.3.1 Background 
Leishmaniasis is a neglected tropical disease [138, 139], and is regarded as the third most 
important vector-borne disease, after malaria and African trypanosomiasis. Globally, 
leishmaniasis is ranked at 9th place, with respect to the burden of disease of all infectious as 
well as parasitic diseases [140]. The causative agent, the Leishmania parasite, is an obligate, 
intracellular microorganism that belongs to the trypanosomatida protozoan genus [138, 139, 
141, 142]. It is estimated that approximately 350 million people are at risk of contracting 
leishmaniasis [143, 144] which is endemic in 98 countries, occurring over five continents [143, 
145]. Each year, roughly 900 000 to 1.3 million cases arise, with 20 000 to 30 000 deaths 
occurring [139, 141, 145]. Furthermore, leishmaniasis is associated with approximately 2.4 
million disability-adjusted life years [144, 146, 147]. 
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Leishmaniasis occurs when Leishmania parasites are transmitted to a vertebrate host by the 
bite of a female Phlebotomine sandfly (2 to 3 mm insects) [139, 142, 148]. Approximately 70 
species of animal hosts commonly infected include humans, cats and dogs. There are over 20 
species of Leishmania parasites that cause the disease, and over 90 species of sandflies 
responsible for transmission [139, 142, 148]. In humans, the clinical forms of the leishmaniasis 
may be classified into one of three groups: visceral leishmaniasis (VL) (also known as kala-
azar), which is the most lethal form; cutaneous leishmaniasis (CL), the most common form; 
and muco-cutaneous leishmaniasis (also known as espundia) [139-142]. 
Visceral Leishmaniasis may be caused by one of the following parasites: L. donovani; L. 
infantum; L. chagasi; or L. amazonensis. If left untreated, VL is fatal in most cases (over 95%). 
Symptoms of VL include irregular episodes of fever, night sweats, enlargement of the liver and 
spleen, anaemia, weakness, anorexia, and weight loss [139, 144, 149, 150]. Diagnosis of VL 
includes serological diagnosis e.g. ELISA, and parasitological diagnosis e.g. using aspirates of 
the spleen, bone marrow or lymph nodes [139, 144, 151, 152]. Every year, approximately 
200 000 to 400 000 new cases of VL occurs globally. Visceral leishmaniasis is endemic is East 
Africa and the Indian subcontinent. The species of Leishmania parasite responsible for visceral 
leishmaniasis varies with location: L. donovani in the Africa, Asia, and the Indian subcontinent; 
L. infantum or L. chagasi in southwest and central Asia the Mediterranean region, and South 
America (primarily in young children); L. amazonensis in South America; and L. tropica in the 
Middle East [139, 146, 147, 153]. A sequel of VL, Post-kala-azar dermal leishmaniasis 
(PKDL), also exists. This manifests as a nodular rash on the face upper arms, and other parts 
of the body [139, 152-154]. Treatment of VL includes the use of the first-line drugs pentavalent 
antimonials, as well as the second line drugs amphotericin B and amphotericin B in liposomes 
[76, 139, 144, 152, 155]. 
Cutaneous leishmaniasis presents as ulcerations on the dermis or skin, and is generally 
localized to tissue that surrounds the inoculation site, however, during a chronic type infection, 
the  parasites can migrate to the draining lymph nodes [139, 140, 144, 156], and roughly 90% 
of all cases occurs in Afghanistan, Pakistan, Syria, Saudi Arabia, Algeria, Islamic Republic of 
Iran, Brazil, and Peru [147, 157]. CL may be caused by various parasite species, depending on 
location. Old world CL (Africa, Asia and Europe) is caused mostly by L. major, L. tropica, and 
L. aethiopica, Mediterranean and Caspian sea regions CL includes L. infantum and L .chagasi, 
and New world CL (America) includes L. mexicana, L. amazonenesis, L. braziliensis, L. 
panamensis, L. peruviana, and L. guyanensis. Each year approximately 0.7-1.2 million new 
cases of CL arise [139, 147]. Figure 1.6 illustrates the distribution of reported cases worldwide 
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in the year 2013 [158]. Diagnosis of CL includes parasitological diagnosis based on skin 
smears, and PCR [159-161]. While old world CL lesions are primarily papules, nodules, or 
nodule-ulcers, new world CL presents primarily as ulcerative lesions [144, 160, 162]. CL 
treatment involves the administering of pentavalent antimonials (local for few, small lesions 
and systemically for several, large lesions) [159, 161, 163].  
Mucosal dissemination of cutaneous leishmaniasis or muco-cutaneous leishmaniasis (caused 
by L. braziliensis L panamensis, L guyanensis), may occur in 1-10% of infections [139, 164]. 
Diagnosis of muco-cutaneous Leishmananisis uses serological techniques due to the strong 
humoral response these patients tend to develop [139, 144, 165]. This form of leishmaniasis 
may develop during cutaneous leishmaniasis, or between 1 and 5 years after cutaneous 
leishmaniasis heals [144, 164]. Muco-cutaneous leishmaniasis presents as destructions of the 
mucous membranes of the nose, mouth and the throat, starting with ulcerations at the nares, 
followed by perforation of the nasal septum as well as the formation of destructive 
inflammatory lesions, ultimately causing obstructions in the pharynx or larynx and 
consequently causing disfigurement [139, 166]. Muco-cutaneous treatment includes the 
administering of pentavalent antimonials as above  [144, 167]. 
Control strategies to curb spread of disease includes vector control, and case identification and 
treatment. There have been several approaches made in the development of a vaccine for 
Leishmaniasis, however, to date, none of these have been successful in humans [168, 169]. 
Furthermore, a significant increase in the number of cases has been observed in various parts 
of the world, and may be attributed to different factors, some of which include the following: 
environmental changes that increase exposure to the sandfly vectors; large-scale migrations of 
populations for occupational reasons (border crossing); deterioration in the social and 
economic conditions in especially low income populations; and the rise in leishmaniasis-HIV 
infections [139, 146, 170-173]. For these reasons, efforts to further understand the immune 





Figure 1.6 Global distribution of cutaneous leishmaniasis in 2013. Image sourced from WHO [158]. 
 
 
1.3.2 Life cycle of L. major 
Figure 1.7 demonstrates the life cycle of the Leishmania parasite in the sandfly vector and 
human host. Briefly, a Leishmania infected female sandfly takes a blood meal, during which 
she regurgitates and introduces metacyclic promastigote parasites, along with 
immunomodulatory parasite-derived proteophosphogylcans and salivary factors into the 
dermis of the human host. Numerous cells are recruited to the site of inoculation, including 
macrophages, which phagocytose the promastigotes. These promastigotes, while internalised 
in the cells, transform into aflagellate amastigote parasites. Amastigotes multiply within the 
cells, followed by cell rupturing to release the parasites, and allowing for the infection of 
surrounding phagocytic cells. The cycle continues with the next blood meal feed, when these 
infected cells are taken up by a female sandfly. The amastigotes next transform into 
promastigotes in the midgut, followed by differentiation of procyclic promastigotes into 
infective metacyclic promastigotes. These parasites reside in the midgut, awaiting transmission 





Figure 1.7 Life cycle of Leishmania parasite. The life cycle begins in the midgut of the female sandfly, 
with the differentiation of Leishmania procyclic promastigotes into infective and non-dividing 
metacyclic promastigotes. During her blood feed, the sandfly regurgitates metacyclic promastigotes, 
along with salivary components and immunomodulatory parasite-derived proteo-phosphoglycans. The 
metacyclic promastigotes are next phagocytosed by one of cell types recruited to the infection site, and 
thereafter, metacyclic promastigotes transform into aflagellate amastigotes. The amastigotes undergo 
replication within the host cells, when they become too many, the cells burst to release infective 
amastigotes, ready to infect neighbouring cells. During a blood feed, the sandfly will take up infected 
phagocytes, and the contained amastigotes will transform into promastigotes in the midgut, completing 
the transmission cycle [174]. Image sourced from Kaye et al. [174]. 
 
1.3.3 The immune response to L. major 
The immune response to L. major, more specifically, resistance and susceptibility to the 
parasite, has been extensively investigated, with the use of experimental mouse models. The 
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possible outcome of L. major infection, resistance or susceptibility, is dependent on the cellular 
and humoral responses. CD4+ T helper cells play a major role with a polarised Th1 immune 
response, characterised by the predominant production of IFN-γ, IL-12 and TNF-α, linked to 
resistance; and a polarised Th2 response, characterised by the predominant production of IL-
4, IL-13, IL-10 and TGF-β associated with susceptibility [175-182]. 
The first cells to migrate to the infected sites are the neutrophils. Here, they release 
antimicrobial mediators, and engulf microorganisms, to phagocytose them. Furthermore, 
neutrophils are responsible for killing foreign infectious by creating a potent oxidative burst to 
release toxic mediators [183, 184]. Neutrophils may kill Leishmania parasites or protect them, 
based on the species of parasite as well as the infected host [185]. While L. amazonensis 
promastigotes are killed by neutrophil extracellular traps (NETs) [186, 187], it has been 
demonstrated that salivary proteins transferred from the sand fly during the blood feed has the 
ability to protect the parasites against neutrophil-mediated death [188]. For this reason, it is 
still unclear whether NETs play a role in protection. In the case of L. braziliensis and L. ama-
zonensis, neutrophils aid in controlling infection by interacting with infected macrophages 
[189, 190]. Conversely, the uptake of apoptotic neutrophil cells by macrophage and dendritic 
cells, after infection with L. major, has shown to decrease the activation of the macrophages 
and dendritic cells. This allows the parasite to survive for longer periods, and evade the host 
immune responses [191, 192]. Neutrophils are able to enhance their chances of uptake by 
dendritic cells, due to their increased expression of apoptotic markers, as well as increased CC-
chemokine ligand 3 (CCL3)-dependent recruitment of dendritic cells [193]. Decreased 
activation of dendritic cells, results in reduced Th1 response. Additionally, this inhibits cross-
presentation for CD8+ T cell activation [194, 195]. Murine L. major models have shown that 
the role of neutrophils in the immune response is dependent on the genetic background of the 
infected host infection. In susceptible BALB/c mice, depletion of neutrophil cells was shown 
to inhibit the early IL-4 response, which prevented Th2 driven non-healing response to occur. 
In C57BL/6, however, the depletion of neutrophils had no effect on the course of infection 
[196].  
Inflammatory monocytes and dendritic cells recruited to the site of infection, are the cells 
predominantly infected with Leishmania parasites, during the first few days after infection 
parasites [194]. The recruitment of inflammatory monocytes depends on the production of 
CCL2 by cells at infection site, after activation via the platelet-derived growth factor [197]. 
Unlike monocyte cells which display a strong respiratory burst after infection, and results in 
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early parasite control, the macrophages require activation by IFN-γ for eradication of the 
parasites [197]. Essentially, inflammatory monocytes are necessary for the control of infection. 
The complement protein and opsonin (antibody or substance that binds to foreign micro-
organisms or cells to render them more susceptible to phagocytosis), C3b, binds to L. major, 
allowing for macrophage cells to phagocytose them. The C3b is, however, converted to iC3b, 
by a glycoprotein found on the surface of the Leishmania parasite, gp63, and inactivated in the 
process [198]. Macrophages respond to infection by producing superoxide and hydroxide 
radicals against the parasites, while L. major parasites inhibit this reaction by producing acid 
phosphatases on its surface. Macrophages produce acidic enzymes in an attempt to degrade the 
parasites [199, 200], when lysosomes fuse with the phagosome. L. major circumvents this 
through the use of a proton pump on the surface of the parasite, allowing them to maintain their 
pH at a neutral position. Leishmania Lipophosphoglycan (LPG) is also important for the 
inhibition of the enzymes. The longer the parasites reside in the macrophage cells, the longer 
they evade the immune system [201].  
Reactive oxygen species (ROS) is produced by the respiratory burst that follows uptake during 
the phagocytic process. Nitric oxide (NO), is produced by inducible NO synthase (iNOS) that 
occurs after cells are activated by IFN-γ. These two products are crucial in L. major parasite 
control. Leishmania parasites are sensitive to ROS, however, respiratory burst in non-activated 
macrophages after infection is not sufficient in killing the parasites [202]. This may be resultant 
of the ability of parasites to inhibit the generation of ROS in phagolysosomes [203]. IFN-γ 
does, however, improve respiratory burst in the macrophage cells, which allows for better 
parasite clearance [204]. In order for macrophages to be sufficiently and optimally activated 
for parasite clearance, the induction of iNOS by IFNγ and tumour necrosis factor (TNF) needs 
to occur [205, 206]. NO diffuses across the cell membrane, and can mediate killing of 
intracellular parasites contained within the NO-producing cell, as well as parasites contained 
in neighbouring cells [207]. While mouse models have demonstrated that NO is crucial in 
Leishmania parasite control [208], their role in humans remains unclear.  
In mice, IL-12 is important in the development of the CD4+ Th1 cells, and a protective response 
[209, 210], while the predominant secretion of  IL-4 leads to the promotion of the development 
of CD4+ Th2 cells and susceptibility [211]. Dendritic cells are the primary source of IL-12, and 
initiates antigen-specific immunity to Leishmania [212]. While some dendritic cells that prime 
the naive T cells reside in the draining lymph node [213], majority results from the recruitment 
20 
 
of inflammatory monocytes to the cutaneous lesion, which differentiate into monocyte-derived 
dendritic cells that travel to the lymph node [214].  
Prior to Th1 cell development, the natural killer (NK) present in the draining lymph node (and 
are closely situated to the dendritic cells) are the main source of IFN-γ [215]. After NK cells 
are  activated, they are recruited to the paracortex and produce IFN-γ [216], promoting IL-12 
production by DCs. Regulates of the NK cell response is brought about by the production of  
Transforming growth factor β (TGFβ), which reduces the  production  of IFN-γ [217]. CD8+ 
T-derived IFN-γ may also drive the early adaptive immune response to L. major, but this is 
dependent on the extent of the initial infection [218, 219]. 
As explained above, CD4+ Th1 cells are needed to control L. major infections. Following 
infection, CD4+ Th1 cells are recruited to the lesions, and produce IFN-γ which activates 
macrophages for parasite clearance. In humans suffering from cutaneous leishmaniasis, an 
additional cell population, is expanded and present. These are identified as double-negative T 
cells, and do not express CD4 or CD8, however, do express CD3 and αβ TCR. Similarly, in L. 
major-mouse studies, a double-negative T cell population has been identified. While these cells 
may by phenotypically different to the classical CD4+ T cells, exhibiting an innate cell-like 
gene expression profile, they proliferate, as well as secrete IFN-γ upon MHCII antigen 
recognition of L. major, similar to classical CD4+ T cells, and therefore do contribute to 
immunity [220, 221].  
Despite clearance and resolution of infection, some parasites may remain as a result of the 
downregulation of the immune response by IL-10 [222], and these persistent parasites retain a 
population of short-lived Leishmania-specific T cells, the effector CD4+ T cells, which may 
respond immediately in the event of re-infection. Additionally, there are short-lived 
Leishmania-specific T cells with an effector memory T cell, and long-lived central memory T 
cells [223]. CD4+ central memory T cells travel to the draining lymph node, proliferating and 
differentiating into effector T cells, which then travel to the site of the lesion [223, 224].  
The role of Treg cells in humans is still unclear, in contrast to their role in mice [225]. IL-10 is 
an important regulator of immunity in murine Leishmaniasis. During infection with L. 
amazonensis and L. panamensis, in mice that received Treg cells from an infected mouse prior 
to infection, pathological responses were reduced, and disease progression halted, evident in 
decreased lesion sizes and lower parasite burdens, and  reduces lesion development. This 
demonstrated that Treg cells may control immunopathological responses [225, 226]. During L. 
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major infection, mice lacking IL-10 have been shown to control the replication of parasites 
[227, 228]. Sources of IL-10 include Th1 cells, Treg cells, B cells  [229] and macrophages that 
have been exposed to IgG-coated L. major amastigotes [227].  
B cells also have the ability to stimulate CD4+ T cells [230, 231]. Recent studies have 
demonstrated that B cells are required for susceptibility to infection with L. major strain LV39 
in BALB/c mice, and were shown to play an important role as APCs, instructing the 
development of a Th2 polarised response [232]. In response to a Th1 polarised response, B 
cells will secrete the Type 1 antibodies IgG2a, IgG2b and IgG3, while stimulation of B cells 
by Th2 characteristic IL-4, leads to isotype switching to produce Type 2 IgG1 and IgE 
antibodies [233].  
1.3.4 IL-4/IL-4Rα signalling in cutaneous Leishmaniasis 
Experimental infections in mice have been extremely useful in gaining insight on the roles of 
IL-4 and IL-4Rα in L. major infection. More specifically, the use of cell-specific IL-4 and IL-
4Rα knock-outs as described above, have been instrumental in providing information on the 
role for this cytokine/receptor pair in L. major infection. Early mouse studies demonstrated that 
generally susceptible BALB/c mice that lacked IL-4 demonstrated a resistant phenotype when 
infected with L. major, and were able to control the progression of disease [179]. During the 
acute phase of L. major infection in IL-4-/- and IL-4Rα-/- deficient BALB/c mice, animals 
appeared to control the infection, evident in reduced swelling and parasite burdens, with 
predominant Th1 and Type 1 antibody responses. Over a longer period, however, in the chronic 
stage, IL-4Rα-/- mice appeared to be highly susceptible, seen in increased disease progression, 
with increased swelling and necrosis of the lesions on the footpad [233]. Abrogation of IL-4 
signalling on CD4+ T cells was shown to be required to transform susceptible non-healing 
BALB/c mice to a resistant healing phenotype, which was evident in the decreased swelling 
and low parasite burdens [132]. A study to ascertain whether the signalling of IL-4Rα on 
macrophage cells in BALB/c mice (LysMcreIL-4R-/flox BALB/c) is required for protection 
during L. major infection, demonstrated that the mice lacking the receptor on these cells, had 
delayed progression of disease, predominant type 2 Ab responses, and significantly increased 
levels of IFN-γ. These authors demonstrated that alternatively activated macrophages play a 
role in the susceptible phenotype in non-healing BALB/c mice [234]. A study of note is the 
work carried out by Biedermann et al., who demonstrated the principle of the “IL-4 instruction 
theory” [235]. Here they showed that IL-4 can instruct dendritic cells to drive a Th1 polarised 
immune response, evident in in vitro experiments where the production of IL-12 and IFN-γ 
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was increased, on the addition of IL-4 to bone marrow-derived dendritic cells. In vivo mouse 
experiments, demonstrated decreased swelling and lesion sizes, when mice were administered 
recombinant IL-4 within the first 8 hours of infection, supporting a Th1 resistant phenotype as 
above.  Conversely, when IL-4 was administered after 12 hours, IL-4 was upregulated and IFN-
γ downregulated. This suggested that early IL-4 was required to drive a Th1 response. More 
recently, dendritic cell-specific IL-4Rα BALB/c mice infected with L. major, showed hyper 
susceptibility to infection, seen in significantly higher swelling and parasite burdens, as well 
as an upregulation of Th2 cytokines and type 2 antibodies. This indicated that IL-4Rα-
responsive dendritic cells are crucial to the hosts survival  [135], and further supported the 
findings reported by Biedermann et al. [235]. 
 
1.3.5 A role for keratinocytes 
During the blood-feed, the sand fly causes significant damage to skin, which results in the 
rupturing of the dermis and capillaries within. This creates a blood “pool” which contains 
extracellular matrix (ECM) constituents from the skin tissue and blood, including a variety of 
cells [236, 237]. This occurrence attracts the neutrophils [237], and macrophage cells, which 
are the primary host cell type for the Leishmania parasites [238]. This interaction facilitated 
between promastigotes, the ECM, and the immune cells is crucial in the establishment of the 
infection, as well as the immune response elicited. Given the situation of keratinocytes in the 
epidermis, these cells are bound to play some role in the immune response against L. major. 
The presence of L. major promastigotes has been shown to rapidly induce keratinocytes to 
secrete immunomodulatory mediators such as IL-12, IL-1β, IL-4, and IL-6, in a study using 
laser-microdissection and in-situ-hybridization. Notably, the secretion of IL-6 by these cells 
was found to be higher in genetically resistant mice, when compared to the levels in susceptible 
ones, and mice with a selective deficiency for IL-6 in non-hematopoietic cells demonstrated a 
non-healing phenotype. In addition, the secretion of the Th2 cytokine IL-4 from keratinocytes, 
as determined by laser microdissection and PCR techniques, was also significantly highly 
present in surprisingly, resistant C57BL/6 mice and to a lesser extent in BALB/c mice. Early 
local neutralization of the IL-4 in these resistant mice resulted in a Th2 switch, rendering these 
mice susceptible [239]. This further supports the suggestion that keratinocytes play a crucial 
role in immune response elicited against Leishmania. Considering the findings that early IL-4 
instructs dendritic cells to drive a Th1 response [235], and that keratinocytes at the infected site 
have been shown to have upregulated IL-4 in resistant mice [239], we hypothesize that the 
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Schistosomiasis is a neglected tropical parasite disease (acute and chronic) caused by blood 
flukes, the trematode flatworms, belonging to the Schistosoma genus. It is also referred to as 
bilharzia and snail fever. Of the 72 countries in which schistosomiasis currently occurs in, it is 
endemic in 52 of them [240, 241]. The global distribution of schistosomiasis in 2011 is 
illustrated in Figure 1.8 [242]. Each year, schistosomiasis affects approximately 200 million 
people, killing more than 100,000 individuals, with the greatest number of cases occurring in 
Africa, the Eastern Mediterranean and the Americas. The causative agents of Schistosomiasis 
in humans includes S. mansoni, S. japonicum, S. haematobium, and S. intercalatum. Our study 
focuses on S. mansoni, which occurs primarily in Africa, the Middle East and Latin America 
[241, 243-245]. Schistosomiasis is a major public health concern in some countries, due to 
aspects that favour transmission of the disease in endemic areas, including poor socioeconomic 
conditions, the use of contaminated water, difficulties in access to health services, and 
inadequate water and sewage treatment [244, 246, 247]. The symptoms experienced during 
schistosomiasis are a result of the reaction of the hosts’ body to the Schistosoma worm eggs. 
These include abdominal pain, diarrhoea, bloody stools, and the enlargement of spleen and 
liver organs, among others. [241, 244]. Diagnosis may include physical examination to perform 
abdominal palpation, to look for hepatomegaly and/or splenomegaly. The gold standard test 
for diagnosis of schistosomiasis is, however, microscopic examination of excretory remains 
(stool, urine) [248]. The control against all forms of schistosomiasis is primarily preventive 
chemotherapy using the trematodicide Praziquantel, which is effective and safe, as well as 
fairly affordable [241, 244, 248, 249]. There have been over 100 schistosome vaccine antigens 
that have been identified, however, only a quarter of these have displayed some level of 
protection when tested using murine models of schistosomiasis. Unfortunately, only three 
molecules, S. mansoni fatty acid binding protein (Sm14), S. mansoni tetraspanin (Sm-TSP-2) 
and S. haematobium glutathione S-transferase (Sh28GST), have progressed to human clinical 
trials, while a fourth, Smp80 (calpain), is at the non-human primate stage of testing [250-252]. 
Due to high mortality and morbidity, the fact that Schistosoma infections appear to increase 
the risk of HIV [253-255], and the concerns about co-infections with Salmonella and 
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Schistosoma [256], there is a great need for new drug and vaccine targets against 
schistosomiasis.  
 
Figure 1.8 Global distribution of schistosomiasis in 2011. Image sourced from WHO [242]. 
1.4.2 Life cycle of S. mansoni 
Transmission of schistosomiasis in humans begins when they encounter contaminated water. 
The cercariae stage of the parasite, freely swims in fresh water, and on contact with human 
skin, and with the use of proteolytic enzymes, penetrates it. Once inside the human host body, 
the cercariae transforms into schistosomula, shedding their forked tail, and locates to the 
vasculature of the host. The larvae migrates to the peripheral vessels, lung and liver, where 
they maturate and eventually mate in the liver vessels to form adult worms. After cercariae 
penetrating the skin, the schistosomula require approximately 5 to 7 weeks to transform into 
adult worms. The male and female adult worms reside within the portal veins, where they will 
eventually mate to produce fertilised eggs which the females lays there. The eggs produce 
proteases that induce inflammatory reactions which is required for them to be passively 
transferred through the walls of the intestine and the bladder, to ultimately be eliminated in 
stool and urine. Some eggs are retained in host, and become trapped in the liver tissues, causing 
an immune reaction. Here they induce inflammation, form granuloma structures and fibrosis 
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around them, and eventually die, resulting in organ damage. The eggs, regardless of their fate, 
will only survive between 1 to 2 weeks after they are released by the female worm. The eggs 
excreted into freshwater eventually hatch to release the next stage of the parasitic worm, the 
free-living ciliated miracidia, which is ready to infect a fresh waters mollusc snail host. The 
snail hosts include the genus Biomphalaria, and the species Biomphalaria glabrata and B. 
tenagophila, B. straminea. In the snail host, the parasite will undergo asexual replication 
through sporocyst stages and will eventually shed tens of thousands of cercariae, ready to infect 
a human host. The cercariae have an infective period in freshwater of 1 to 3 days, however, 
their energy reserves begin to reduce greatly over a few hours. This marks a full cycle. During 
the lifecycle in the snail, the asexual period requires approximately 4 to 6 weeks before the 
cercariae are released for human infection [257-260]. The life cycle of the of S. mansoni, S. 
haematobium, and S. japonicum are illustrated in Figure 1.9 [257]. 
 
Figure 1.9 The life cycle of S. mansoni, S. haematobium, and S. japonicum. (A) Paired adult male 
and female worms (larger male enfolding slender female), (B) egg stage (from left to right, S. 
haematobium, S. mansoni, S. japonicum), (C) ciliated miracidium stage, (D) snail hosts (from left to 






1.4.3 The immune response to S. mansoni 
Murine models have provided extensive insight into the immunology of schistosomiasis. Both 
cellular and humoral antibody responses are required for optimal protection against 
schistosomiasis [261]. T cell-deficient mice have indicated crucial roles for immune responses 
to the maturation of worms, as well as the formation of granuloma structures [262, 263]. The 
hosts’ immune response may be divided into three phases according to the predominant 
immune response elicited. The first phase occurs 3 to 5 weeks after exposure to parasites, and 
is characterised by a balanced or dominant Th1 immune response to the parasite antigens [264]. 
Phase 2 commences around 5 to 6 weeks post-infection, when eggs are produced. During this 
time, the Th1 response decreases, while a Th2 response becomes the dominant response as a 
result of the eggs, and the formation of granuloma structures encapsulating the eggs [134, 265, 
266]. This immunologic shift is due to the interaction of specific schistosome egg antigens with 
dendritic cells, and partially through the action of certain carbohydrate epitopes [267]. Th2 
immune responses provide a protective function, and sufficient regulation can minimize overall 
pathology in the host. When Th2 responses are depleted, specifically IL-4, tissue damage and 
host mortality occurs as a result of pro-inflammatory Th1-type responses [268, 269]. The 
chronic phase occurs from 10 weeks post-infection. During this phase of the immune response, 
the Th2 immune response is downregulated with the development of a strong regulatory T cells 
response, inducing less fibrosis and the formation of granulomas around new eggs which are 
smaller in size than those produced during the acute infection [270-273]. Other 
immunomodulatory mechanisms include IL-10 secretion, B cells and antibodies [243, 274]. 
1.4.4 IL-4/IL-4Rα signalling in schistosomiasis 
As mentioned above, murine studies have been helpful in better understanding the 
immunological response elicited against S. mansoni infection. The use of genetically modified 
mice has given us great insight into aspects that contribute to disease outcome during S. 
mansoni. During S. mansoni infection, global IL-4 (IL-4-/-) knockout mice appeared to be 
susceptible to disease, indicating a role for this cytokine in protection [265]. In the absence of 
both IL-4 and IL-10 (double knockout), mice appeared to be highly susceptible to disease, and 
demonstrated upregulated levels of Th1 IFN-γ and TNF-α, with increased liver and gut 
pathology [270]. The IL-4Rα/STAT pathway has also been explored for their role in S. mansoni 
disease. Mice lacking IL-4Rα-/- and STAT6-/- demonstrated high susceptibility when infected 
with S. mansoni, evident in the downregulation of Th2 cytokines, inflammation in organ 
tissues, and reduction in fibrosis [275, 276]. In our laboratory, cell-specific IL-4 and IL-4Rα 
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knockout mice generated using the Cre/loxP recombination system as described above, has 
been useful in demonstrating roles for these components during S. mansoni infection [277]. 
Various cell types have been explored for the contribution of the IL-4Rα found on their 
surfaces, to S. mansoni protection and susceptibility. Mice that lacked IL-4Rα signalling on 
macrophage and neutrophil cells were highly susceptible to S. mansoni during the acute stage, 
and the data indicated that alternative macrophages are required for protection during S. 
mansoni [134]. Studies investigating the signalling of IL-4Rα on pan-T cells [130], as well as 
smooth muscle cells [136], showed that while these mice were able to control inflammation in 
the gut, they were still susceptible to S. mansoni infection, indicating a protective role for IL-
4Rα on these cells. 
1.4.5 A role for keratinocytes 
The skin plays an important part in the life cycle of S. mansoni. The cercariae need to efficiently 
and effectively penetrate the skin and migrate through this barrier and its components, while 
evading any protective mechanisms. The response of keratinocytes to invading cercariae has 
not been well studied. An early study demonstrated that when mice were infected with S. 
mansoni, the keratinocytes responded by secreting IL-7 [278]. Recently, Bourke et al. 
demonstrated that S. mansoni cercariae, as well as their excretory and secretory products may 
act directly upon epidermal keratinocytes, causing them to respond by initiating barrier repair 
and pro-inflammatory mechanisms, as observed during epidermal wound healing [279]. 
Considering the protective role IL-4 and IL-4Rα appears to play in S. mansoni, the importance 
of the skin during infection, and the secretion of keratinocyte-derived IL-4 as a Th2 driving 
factor as suggested by Ehrchen et al. during L. major infection [239],  we postulated that IL-
4Rα keratinocytes would play a role in protection during S. mansoni.   
1.5 Objectives of the present study 
The purpose of this study was to determine whether IL-4/IL-13 signalling through the IL-4Rα 
on keratinocytes, plays a role in the outcome of disease, using two in vivo infection mouse 
models that require penetration of the skin for establishment of infection. 
1. Leishmania major  




Chapter 2: Deletion of IL-4Rα-responsive keratinocytes during cutaneous leishmaniasis 
causes minor immunological changes in BALB/c and C57BL/6 mice, but does not affect 
their susceptibility and resistance to infection respectively  
2.1 Introduction 
The skin is an immune organ, whose primary cell type is keratinocytes [39], and in parasitic 
infections such as cutaneous leishmaniasis, infective Leishmania major (L. major) 
promastigotes are injected into the skin by the female sandfly. The promastigote parasites 
migrate through this barrier and its components, and establish infection. Due to the abundance 
of keratinocytes in the epidermis, it would not be surprising if these cells could play 
immunomodulatory roles during L. major infection. Experimental mouse models for L. major 
infections provide a good indication of the immune response elicited against it, which is 
polarised to either a T helper (Th) 1 or Th2 response, resulting in either resistance or 
susceptibility to the infection, respectively. While a Th1 response is characterised by classical 
activation of macrophages via the cytokines interferon gamma (IFN-γ) and interleukin (IL)-12 
production, the Th2 response is characterised by alternative activation of macrophages, via the 
production of various cytokines including IL-13, IL-5, and primarily IL-4, which signals via 
the IL-4 Receptor alpha chain (IL-4Rα). Previous studies have well-demonstrated that a 
resistant phenotype is observed in C57BL/6 mice, while a susceptible phenotype is observed 
in BALB/c mice [175-179]. While it is known that IL-4 generally induces a Th2 response, 
some reports have recently demonstrated that an early production of IL-4 at the site of infection, 
may in fact drive a Th1 response, under the instruction of dendritic cells [135, 235]. This is 
further supported by the fact that both BALB/c and C57BL/6 mouse strains secrete IL-4 early 
after L. major infection [78]. Furthermore, a recent study demonstrated that in the presence  of 
L. major IL-81 promastigotes, keratinocytes are rapidly induced to secrete immunomodulatory 
mediators including IL-12, IL-1β, IL-4, and IL-6, and suggested that the keratinocytes may be 
providing the early IL-4 that  instructs DCs to drive the Th1 response [239].  
The IL-4Rα chain controls the biological functions of IL-4 and IL-13 [98], thus in order to 
block IL-4/IL-13 signalling on keratinocytes, we can block the signalling receptor on this cell. 
To ascertain whether IL-4/IL-13 signalling by keratinocytes is crucial in the outcome of 
cutaneous Leishmania disease, we generated a keratinocyte-specific IL-4Rα deficient mouse 
on a BALB/c and C57BL/6 genetic background (KRT14creIL-4Rα-/lox mice) and infected these 
mice with L. major IL-81 or LV39 to analyse disease progression and host immune responses. 
We found that in the footpad infection model, abrogated IL-4/IL-13 signalling via IL-4Rα on 
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keratinocytes, KRT14creIL-4Rα-/lox BALB/c mice developed increased footpad swelling, high 
parasite burdens, both Th1 and Th2 immune responses, and high type 1 and type 2 antibody 
responses, similar to littermate control mice. On a C57BL/6 genetic background, in the footpad 
infection model, we saw that the deletion of IL-4/IL-13 signalling via IL-4Rα on keratinocytes 
resulted in KRT14creIL-4Rα-/lox C57BL/6 mice developing low footpad swelling, low parasite 
burdens, stronger Th1 immune responses, and low type 1 and type 2 antibodies, similar to 
littermate control mice on the C57BL/6 genetic background. In the ear infection model, the 
absence of signalling of IL-4/IL-13 via IL-4Rα on keratinocytes resulted in KRT14creIL-4Rα-
/lox BALB/c mice showing increased ear swelling, high parasite burdens, high Th1 and Th2 
immune responses, and high type 1 and type 2 antibody responses, similar to littermate control 
mice. Additionally, the absence of IL-4Rα-responsive keratinocytes contributed to the control 
of parasites in the ears of these KRT14creIL-4Rα-/lox BALB/c mice. Finally, on a C57BL/6 
genetic background, in the ear infection model, we saw that abrogated IL-4/IL-13 signalling 
via IL-4Rα on keratinocytes resulted in KRT14creIL-4Rα-/lox C57BL/6 mice developing low ear 
swelling, low parasite burdens, stronger Th1 immune responses, and low type 1 and type 2 
antibodies, similar to littermate control mice on the C57BL/6 genetic background. While 
immune responses may have been influenced in some cases, KRT14creIL-4Rα-/lox mice on the 
BALB/c genetic background were still non-healing, and KRT14creIL-4Rα-/lox mice on the on 
the C57BL/6 genetic background could still heal lesions.  
2.2 Materials  
All general reagents were purchased from either of the following suppliers: Merck Chemicals 
(Pty) Ltd.; Gibco Life Technologies; Corning, Invitrogen Life Technologies, Roche, and Sigma 
Aldrich. Molecular biology reagents were purchased from ThermoScientific, BD Bioeciences 
and Fermentas Life Sciences. See Appendix for reagents for all experiments. 
2.3 Methods 
2.3.1 Ethical statement 
All mouse experiments and protocols were performed in strict accordance with the South 
African national guidelines, as well as the Animal Research Ethics Committee of the Faculty 
of Health Sciences, University of Cape Town (license no. 015/034). All efforts were made to 
minimise and reduce suffering of animals. 
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2.3.2 Generation and genotyping of KRT14creIL-4Rα-/lox mice 
Keratinocyte cell-specific IL-4Rα-deficient (KRT14creIL-4Rα-/lox) BALB/c mice were 
generated using the Cre/loxP system, and characterized by our laboratory (unpublished). 
Briefly, KRT14cre mice (Stock Tq (KRT14cre) 1Amc/J-Jackson laboratory) were crossed with 
IL-4Rα-/- BALB/c mice [233] and transgenic IL-4Rαlox/lox mice [134] to generate hemizygous 
KRT14creIL-4Rα-/lox BALB/c mice. These KRT14creIL4Rα-/lox mice were also generated on a 
C57BL/6 background in our laboratory. All cutaneous leishmaniasis experiments included the 
following mouse groups (BALB/c or C57BL/6 background): KRT14creIL4Rα-/lox, hemizygous 
(also wild-type) littermate controls (IL-4Rα-/lox), wild-type BALB/c, global IL-4Rα-/- and 
C57BL/6 mice. All mice were kept under specific pathogen-free conditions, in individually 
ventilated cages. Experimental mice were age and sex-matched, and used between 8 to 10 
weeks of age. Genotyping of KRT14creIL-4Rα-/lox BALB/c and C57BL/6 mice was carried out 
by Miss Munadia Ansarie at the Division of Immunology, using specific primers: KRT14 P1, 
5'- TTC CTC AGG AGT GTC TTC GC; KRT14 P2, 5'- GTC CAT GTC CTT CCT GAA GC; 
KRT14 P3, 5'- CAA ATG TTG CTT GTC TGG TG; KRT14 P4, 5'- GTC AGT CGA GTG 
CAC AGT TT. IL-4Rα deletion was confirmed with flow cytometry, staining for the IL-4Rα 
on ear-isolated keratinocytes (Joint experiment by the author and collaborators at the 
University Of Lausanne, Switzerland) (unpublished). The isolation of keratinocytes from the 
ear, and staining for IL-4Rα were performed by the author, assisted by Dr. M. Descatoire, at 
the University Of Lausanne, Switzerland, in the Tacchini-Cottier laboratory. The protocols 
were developed in the Tacchini-Cottier laboratory. Briefly, ears were digested in complete 
Dulbecco's Modified Eagle's Medium (cDMEM) containing liberase (TL research grade, 
Roche). The reaction was stopped with EDTA, ear samples were crushed through a 40 µM 
filter, and the supernatant centrifuged. Cells were then counted and labelled. Labelling was 
performed by adding the antibodies for 20 minutes on ice, followed by the addition of the 
secondary antibody. Keratinocytes were gated as CD45- and were double positive for CD49 
and K14. Antibodies included CD45-PerCP, CD49f-FITC, mouse anti-Keratin 14 and Goat 
anti-mouse A555. CD45- CD49+ K14+ keratinocytes were then stained for the presence of IL-
4Rα with IL-4Rα-PE, and samples were acquired on the Fortessa machine (BD, San Jose, CA, 





2.3.3 L. major infection  
L. major strains: LV39 sub strain obtained from American Type Culture Collection  (ATTC) 
50132 strain (MRHO/SU/59/P) and LV39 sub strain (MRHO/SV/59/P) obtained from the 
University of Lausanne [180, 280]; L. major IL-81 (MHOM/IL/81/FEBNI); and GFP-
expressing L. major IL-81 (MHOM/IL/81/FEBNI) (kind gift from Prof. Heidrun Moll, 
University of Würzburg, Germany) were maintained via continuous passage through BALB/c 
mice [233], and in vivo cultures were incubated in Schneiders media (Sigma-Aldrich) 
supplemented with 20 % fetal calf serum (FCS) in a tissue flask (Corning). Parasites were 
prepared for infection as previously described [233]. Briefly, parasites were harvested from the 
footpad lesion and popliteal lymph node of an infected mouse, followed by in vitro culturing 
at 37°C, in a tissue culture flask containing 10 ml Schneiders’ medium supplemented with 20 
% FCS (SCH+FCS medium). Parasite growth was monitored over a 7 day period, after which 
confluent parasites were fixed in 2% gluteraldehyde, counted using a Neubauer cytometer 
slide, and prepared for murine infection studies. Mice were anaesthetised prior to subcutaneous 
inoculation with 2×105 (IL-81) or 2×106 (LV39) stationary phase metacyclic promastigotes, 
into the left hind footpad, contained in a volume of 50 µl of phosphate buffered saline (PBS) 
[132, 135, 233]. Disease progression was monitored weekly, by measuring change in swelling 
of infected footpads, using a Mitutoyo micrometer caliper (Brütsch, Zürich, Switzerland). 
Alternatively, mice received an intradermal inoculation with 1×104 stationary phase metacyclic 
promastigotes, into the left ear, contained in a volume of 10 µl of PBS [281-283]. Disease 
progression was monitored weekly, by measuring change in diameter of lesion of infected ear, 
using a vernier calliper (South Africa). In the footpad infection model, mice infected with L. 
major LV39 were sacrificed at 8 weeks post infection (p.i.) whilst mice infected with L. major 
IL81 strains were sacrificed at 6 weeks p.i. In the ear infection model, mice were sacrificed at 
8 weeks p.i. regardless of infecting strain.  
2.3.4 Preparation of soluble Leishmania major antigen (SLA) 
Parasites were recovered from in vitro cultures as described in Section 2.3.3. SLA was prepared 
from these stationary phase metacyclic promastigotes as follows: parasites were centrifugated 
at 5000 rpm for 10 min at 4°C, the pellet re-suspend in 1 ml PBS-containing cocktail protease 
inhibitor (Sigma-Aldrich)  and transferred to a Greiner tube, the re-suspension sonicated to lyse 
the cells (4 x 20 sec with 20 sec rest period), the solution transferred to a sterile eppendorf and 
centrifuge at 8000 rpm for 10 min at 4 °C, and the supernatant filtered through a 0.22 µM filter. 
The concentration of the SLA was determined using a Pierce® bicinchoninic acid protein assay 
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(BCA), which was carried out as recommended by the manufacturer. A 2 mg/ml bovine serum 
albumin (BSA) stock solution provided was used to produce protein standards. SLA was stored 
in aliquots at -80 °C until required.  
2.3.5 Determination of viable parasite burden 
The limiting dilution assay (LDA) was used to quantify viable parasite burden [233]. The 
infected footpad, ear, and spleen were collected in 2 ml SCH+FCS medium, whilst draining 
lymph nodes were collected in 1 ml cDMEM. Draining lymph nodes were processed through 
a 40 μM strainer to obtain single cell suspensions in a final volume of 6.4 ml (100 μl equivalent 
to 26 parasites). Two-fold serial dilutions were prepared in 96 well NUNC flat-bottom plates 
using SCH+FCS medium in a final volume of 100 μl. 7 days post-incubation at 37°C, 
individual wells were examined and scored microscopically for the presence or absence of 
parasite growth.  
2.3.6 Isolation and stimulation of draining lymph node cells 
Single cell suspensions (prepared as described in Section 2.3.5) were centrifugated at 1500 rpm 
for 5 min at 4°C and filtered through 40 um filter. Pelleted cells were re-suspended in 3 ml 
cDMEM, and viable cells were counted using Trypan Blue to exclude dead cells. Cells were 
made to 1×107 (100 μl equivalent to 1 million cells). The cells were then cultured in triplicate 
at 1×106 /ml in 48-well flat-bottom plates, and left unstimulated, or stimulated with 20 μg/ml 
anti (α)-CD3 or 50 μg/ml soluble L. major antigen (SLA). Cells were incubated at 37°C and 
5% CO2. After 48 hrs, plates were centrifuged and supernatants were removed and used for 
the detection of the following cytokines: IFN-γ; IL-4; and IL-13, using enzyme-linked 
immunosorbent assay (ELISA). 
2.3.7 Flow cytometry 
Draining lymph node cells from L. major infected mice were prepared (as described in Sections 
2.3.5 and 2.3.6) and seeded (in a 96 well NUNC plate) for intracellular cytokine (IC) staining 
(2×106  cells per well), and cell populations (1×106  cells per well). For cell populations, cells 
were centrifugated in NUNC V-bottom plates, and the pellets were re-suspended and stained 
in 50 μl antibody mix for 30 min in foil at 4°C. After incubation, 150 μl FACS buffer was 
added, and cells were spun down, followed by the re-suspension of cells in 2% 
paraformaldehyde in PBS for fixing, incubated in foil for 30 min at 4°C. Cells were thereafter 
washed in PBS, followed by final re-suspension in 200 μl FACS buffer. The expression of 
surface markers on cell populations (T cells, B cells, dendritic cells and macrophages) were 
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identified using monoclonal antibodies labelled with one of the following: fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC) or peridinin chlorophyll 
protein (PerCP). T and B cell panel included: CD3-FITC; CD4-PE; CD8-APC; CD19-
PerCpCy5.5. Dendritic cell and macrophage panel included:  CD11c-APC; CD11b-PE; 
MHCII-FITC. Each mix also included 1% rat serum and 10 µg FC gamma receptor blocker 
(Fcγ). For IC staining, cells were seeded in 96 well U-bottom plates and stimulated at 37°C for 
2 hours in cDMEM with 50ng/ml phorbal myristate acetate (PMA) and 250 ng/ml ionomycin 
(IONO), followed by the addition of  200 μM monensin, for 4 hrs. Following surface staining 
in 50 μl antibody mix (CD3-FITC, CD4-PerCP, CD8-APC, 1% rat serum, 10 µg Fcγ) for 30 
min in foil at 4°C, cells were washed and fixed as described above, and next permeabilized 
with permeabilization buffer for 30 min in foil at 4°C. Intracellular cytokines were added (all 
cytokine antibodies IFN- γ, IL-4 and IL-13 on PE channel), for 60 min in foil at 4°C, followed 
by a wash and final re-suspension in FACS buffer, ready for acquisition. Acquisition of cells 
was completed on FACS Calibur machine (BD Immunocytometry systems, San Jose, CA, 
USA). Flow data was analyzed using Flowjo software (www.flowjo.com/) (Treestar, Ashland, 
OR, USA). Representative flow cytometry plots and gating strategies are available in the 
Supplementary Figures section. 
2.3.8 Detection of antibody titres with ELISA 
Antibody ELISAs were carried out as previously described [233]. Briefly, at the completion of 
each experiment, blood samples were retrieved via cardiac puncture and collected into serum 
separator tubes (BD Bioscience, San Diego, CA). The samples were centrifuged at 8000 rpm 
for 10 min 4ºC. The indirect ELISA was used to detect antigen-specific levels of IgG2a and 
IgG1. Nunc MaxiSorp flat-bottom 96 well ELISA plates were used. Wells were coated 
overnight at 4°C with SLA diluted in carbonate coating buffer (final concentration: 5 µg/ml). 
Following overnight incubation, the wells were blocked with 2% milk powder for 3 hrs at 37°C. 
Plates were washed 3 times and the serum (diluted 1 in 10 with dilution buffer) was added in 
3-fold serial dilutions, followed by overnight incubation at 4°C. Plates were washed as above, 
and alkaline phosphatase (AP)-labelled specific antibodies were added for 1 hr at 37°C. The 
sandwich ELISA was used to measure total IgE. Wells were coated with IgE clone 84.1C in 
carbonate coating buffer and incubated overnight at 4°C. Wells were washed, blocked, and 
sample added, as described above, followed by the addition of Rat-α-mouse IgE AP. After 
incubation with AP-labelled antibody, plates were washed and 4-Nitrophenylphosphate (PNP) 
added (1 mg/ml dissolved in substrate buffer). Optical density was measured at 405 nm with 
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492 nm as a reference wavelength. Micro-titre plate readings were carried out with a 
VersaMax™ ELISA plate reader. 
2.3.9 Detection of cytokine production with ELISA 
The sandwich ELISA [233] was used to determine the concentration of the following 
cytokines: IFN-γ; IL-4; and IL-13 in cell supernatants obtained in Section 2.3.6. ELISA plates 
were coated with purified anti-IFN-γ (AN18KL6), anti-IL-4 (11B11), or anti-IL-13 (R&D 
MAB413), diluted in PBS coating buffer, and incubated overnight at 4°C. Wells were then 
blocked and washed as described above in Section 2.2.9, flowed by the addition of purified 
recombinant cytokine standards IFN-γ, IL-4, IL-13, or cell supernatants (Section 2.3.6) added 
in 3-fold serial dilutions and incubated overnight at 4°C. Wells were washed, and biotinylated 
anti-mouse secondary antibodies specific for each cytokine, was added for 3hrs at 37°C. Wells 
were then washed and incubated with AP-labelled streptavidin for 1 hr at 37°C, followed by 
incubation with PNP Substrate as above in Section 2.3.8. The reaction was stopped with 1 M 
NaOH and absorbance was read as described in Section 2.3.8. The detection limits for the 
ELISAs were approximately 0.13 ng. Micro-titre plate readings were carried out with a 
VersaMax™ ELISA plate reader. 
2.3.10 Statistics 
Statistical analysis was carried out using GraphPad Prism 5 software (http://www.prism-
software.com). The data was calculated as mean ± SEM. Statistical significance was 
determined using the unpaired Student’s t test or 2-way ANOVA with Bonferroni’s post-test 
(unless otherwise stated), defining differences to IL-4Rα-/lox as significant (*,p≤0.05; 
**,p≤0.01; ***,p≤0.001).  
2.4 Results 
2.4.1 Genotypic and phenotypic characterization of KRT14creIL-4Rα-/lox mice  
Genetically modified BALB/c mice expressing Cre-recombinase under control of the 
keratinocyte cell-specific promoter KRT14 (Jackson laboratory) were inter-crossed with IL-
4Rα-/- BALB/c mice [233] and IL-4Rαlox/lox BALB/c [134] to generate KRT14creIL-4Rα-/lox 
mice (Supplementary Figure 1A). KRT14creIL-4Rα-/lox BALB/c mice were identified by PCR 
genotyping (Supplementary Figure 1B). Analysis of IL-4Rα surface expression on isolated ear 
keratinocytes by flow cytometry demonstrated that IL-4Rα was efficiently depleted in 
KRT14creIL-4Rα-/lox BALB/c mice as seen by the shift of IL-4Rα expression away from wild-
type BALB/c mice (Supplementary Figure 1C). The deletion of IL-4Rα on KRT14creIL-4Rα-
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/lox C57BL/6 mice was also confirmed by PCR (data not shown) and flow cytometry 
((Supplementary Figure 1D). 
 
2.4.2 KRT14creIL-4Rα-/lox BALB/c mice remain susceptible to L. major infection in the 
footpad model similar to littermate control BALB/c mice 
In order to determine whether the signalling molecule IL-4Rα present on keratinocytes at the 
site of infection is important in disease outcome, KRT14creIL-4Rα-/lox BALB/c mice were 
infected subcutaneously in the left hind footpad with stationary phase metacyclic 
promastigotes, either 2×105 L. major of the highly virulent IL-81 strain (Figure 2.1A). The 
footpad infection murine model for leishmaniasis has been well established in our laboratory 
[94, 132, 135, 284], and in other groups [285-287]. As expected, and demonstrated in previous 
reports [132, 233], IL-4Rα-/- BALB/c and C57BL/6 mice controlled the development of lesions 
during acute infection with L. major IL-81 (Figure 2.1A), correlating with the low parasite 
burdens observed in the homogenised infected footpads, draining popliteal lymph nodes, and 
spleens, as determined by limiting dilution assay (LDA). Mice were also infected with 2×106 
L. major LV39 ATTC strain (Figure 2.1B). Interestingly, during infection with this strain, the 
IL-4Rα-/- BALB/c, still exhibiting swelling significantly lower to the littermate (IL-4Rα-/lox) 
control mice, seemed to have a swelling almost identical to that of the wild-type BALB/c mice 
(Figure 2.1B). Parasite burdens for IL-4Rα-/- BALB/c mice infected with L. major LV39 ATTC 
were unexpectedly significantly higher in the draining lymph node, in comparison to the 
littermate control mice (Figure 2.1B). The discrepancy of the phenotype of the IL-4Rα-/- 
BALB/c mice, is due to the difference in sub strain and source of LV39 [288]. In both sets of 
infections, wild-type BALB/c mice developed progressive footpad swelling, as expected of this 
genetically susceptible strain, which was significantly lower than the littermate control IL-4Rα-
/lox mice (Figure 2.1A and 2.1B). We included genetically susceptible wild-type BALB/c and 
littermate control mice in all our experiments, due to a gene-dosage effect for IL-4Rα 
expression that can cause differences in their immunological response [289]. Holmdahl et al. 
also explains the need for littermate control mice to be included in experiments [290]. 
Importantly, during both L. major IL-81 and L. major LV39 infections, the KRT14creIL-4Rα-
/lox BALB/c mice developed progressive footpad swelling similar to littermate control mice, 
and exhibited similarly high parasite burdens in the infected footpads, draining popliteal lymph 
nodes, and spleens (Figure 2.1). These results suggested that deletion of the IL-4Rα on 
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keratinocytes in BALB/c mice does not affect the progression of L. major disease in the 
classical footpad model.  
 
 
Figure 2.1 KRT14creIL-4Rα-/lox BALB/c mice are clinically susceptible to L. major similar to 
littermate control mice in the footpad murine model. Mice were infected subcutaneously in the left 
hind footpad with stationary phase metacyclic L. major promastigotes at either (A) 2 x 105 IL-81 or (B) 
2 x 106 LV39. The change in footpad swelling in mm was measured at weekly intervals (5-7 mice per 
group). Parasite burden was determined at week 6 for (A) and week 8 for (B), by limiting dilution of 
homogenized footpads, single-cell suspensions of the draining popliteal lymph nodes, and homogenised 
spleens. A representative of two individual experiments is shown with mean values ± SEM (Statistical 
analysis was performed with comparisons to the control IL-4Rα-/lox littermate mice group, as significant 
(*, p˂0.05, **, p˂0.01; ***, p˂0.001). Experiments and analysis were carried out by Kaya Gqada and 




2.4.3 KRT14creIL-4Rα-/lox BALB/c mice exhibit a cell population repertoire, cytokine 
profile, and antibody responses model similar to littermate control BALB/c mice during 
L. major infection in the footpad  
Wild-type BALB/c mice are susceptible to L. major infection and demonstrate a Th2 polarised 
immune response [176, 291]. We evaluated the immune response of KRT14creIL-4Rα-/lox 
BALB/c mice during L. major infection to determine whether these mice elicited a polarised 
Th2 immune response, since they presented as clinically susceptible mice. Cell populations 
infiltrating the draining lymph node of KRT14creIL-4Rα-/lox BALB/c mice as determined using 
surface staining, showed no differences when compared to littermate control mice (Figure 2.2A 
and 2.2B). Percentages of the CD3+CD4+ T helper cell were similar in all mouse groups except 
C57BL/6 mice, which showed significantly lower levels. The percentage of CD3+CD8+T 
cytotoxic cells present in the draining lymph node were similar in all groups of mice. CD19+ 
B lymphocytes were similarly high in all mouse groups, however, only C57BL/6 mice had a 
significantly higher percentage of these cells compared to littermate controls. KRT14creIL-4Rα-
/lox BALB/c mice showed similar levels of dendritic cells and macrophages when compared to 
littermate control mice, similar to IL-4Rα-/- and wild-type BALB/c mice, with C57/BL6 mice 
having a higher percentage that was not significant (Figure 2.2B). Levels of macrophages were 
similar in all groups of mice, except the C57BL/6 mice, which had significantly more 
macrophages than the littermate control mice (Figure 2.2B). Cell numbers of the different 
populations followed the same pattern as with percentages (Data not shown). Collectively, 
these results suggest that cellular infiltration in the lymph node occurred independently of IL-
4Rα-responsive keratinocytes during L. major infection in KRT14creIL-4Rα-/lox BALB/c mice. 
To investigate the impact of IL-4Rα deficiency on keratinocytes on the cytokine production by 
CD4+ T helper cells during infection, single LN cell suspensions (as described above) were 
stimulated with PMA/Ionomycin/Monensin and stained for intracellular cytokine production 
(Figure 2.2C). Resistant C57BL/6 mice illustrated significantly higher levels of IFN-γ, and 
significantly lower levels of IL-4 and IL-13, as expected [135], in comparison to littermate 
control mice. KRT14creIL-4Rα-/lox BALB/c and remaining mouse groups, IL-4Rα-/- and wild-
type BALB/c mice, showed similar levels of all three cytokines., with IL-4Rα-/- mice having 
significantly lower levels of IL-13, as compared to littermate control mice. LN cells were also 
stimulated with soluble leishmanial antigen (SLA) or α-CD3 (strong mitogen for T cells) to 
demonstrate cytokine production (Figure 2.2D-F). Similar levels of IFN-γ (Figure 2.2D), IL-4 
(Figure 2.2E) and IL-13 (Figure 2.2F) were observed in KRT14creIL-4Rα-/lox BALB/c and 
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littermate control mice. In contrast to CD4+ T cell cytokine production (Figure 2.2C), C57BL/6 
mice showed significantly lower levels of all three cytokines, when LN cells were stimulated 
with α-CD3 as compared to littermate control mice (Figure 2.2D-F). Stimulation of LN cells 
from wild-type BALB/c mice with both α-CD3 and SLA illustrated similar levels of all 
cytokines in comparison to littermate control mice. When stimulated with α-CD3, IL-4Rα-/- 
mice produced similar levels of IFN-γ (Figure 2.2D), and significantly lower levels of IL-4 
(Figure 2.2E) and IL-13 in comparison to littermate control mice (Figure 2.2F). SLA 
stimulation of LN cells from IL-4Rα-/- mice produced lower levels of IFN-γ which was not 
significant (Figure 2.2D), significantly lower levels of IL-4 (Figure 2.2E) and lower but not 
significant levels of IL-13 (Figure 2.2F) as compared to littermate control mice. The data 
suggests that IL-4Rα responsive keratinocytes do not play a role in driving a Th1 polarised 
response during L. major infection in the footpad mouse model.   
The quantification of cytokine production after ex vivo stimulation may not provide a true 
indication of the Th1 and Th2 responses in vivo [291]. Furthermore, it is known that IL-4 
promotes isotype switching to IgG1 and IgE, and IgG2a levels correlates to the activity of IFN-
γ in vivo [292]. For these reasons, we measured SLA-specific Type 1 (IgG2a) and type 2 (IgG1 
and Total IgE) antibody titres in the mouse sera by ELISA, 6 weeks post-infection with L. 
major IL-81. KRT14creIL-4Rα-/lox BALB/c and littermate control mice illustrated similar higher 
levels of IgG2a (Figure 2.2G), similar lower levels IgG1 (Figure 2H) and similar higher levels 
of total IgE (Figure 2.2I). Compared to littermate control mice, IL-4Rα-/- had significantly 
lower levels of IgG2a, as did wild-type BALB/c mice, as well as significantly lower levels of 
IgG1 and total IgE, similar to C57BL/6 mice. Significantly more IgG1 and IgE was produced 
by wild-type BALB/c mice in comparison to the littermate control mice. Similar observations 
were seen with mice during an L. major LV39 ATTC infection (data not shown). Collectively, 
the data suggested that systemic antibody responses in KRT14creIL-4Rα-/lox BALB/c mice were 
unaffected by the deletion of the IL-4Rα signalling receptor on keratinocytes, during infection 
with L. major IL-81 and LV39 ATTC, in the footpad infection model.  
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Figure 2.2 KRT14creIL-4Rα-/lox BALB/c mice develop an immune response similar to littermate 
control mice during L. major IL-81 infection in the footpad murine model. At 6 weeks post-
infection, mice were sacrificed and popliteal draining lymph nodes retrieved. Single cell suspensions 
obtained from the lymph nodes were extracellularly stained for the following populations: (A) T helper 
(CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); (B) dendritic cells (CD11chiMHCIIhi) 
and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) stimulated with PMA/ionomysin/monensin, 
followed by staining for intracellular cytokine production. Cells were re-stimulated with α-CD3 and 
soluble leishmanial antigen (SLA) for 72 hours, after which cytokine production was measured with 
ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-specific type 1 (IgG2a) and (H-I) type 2 
antibodies (IgG1 and total IgE) were measured in sera from 6 week infected mice by ELISA. Data is 
representative of two experiments. Statistical analysis was performed with comparisons to the control 
IL-4Rα-/lox littermate mice group, as significant (*, p˂0.05, **, p˂0.01; ***, p˂0.001). Experiments and 
analysis were carried out by Kaya Gqada and Dr R. Hurdayal, while figure was compiled by the author. 
 
2.4.4 Resistant phenotype is maintained in KRT14creIL-4Rα-/lox C57BL/6 mice during L. 
major infection in the footpad model similar to littermate control C57BL/6 mice 
C57BL/6 mice are genetically resistant to L. major, mounting a Th1 polarised response during 
infection [176]. A recent study has, however, demonstrated that early neutralization of IL-4 in 
these C57BL/6 mice resulted in a switch to Th2 immune response [239]. Furthermore, the 
authors suggested that the IL-4 driving characteristic Th1 response in C57BL/6 mice may be 
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secreted by keratinocytes at the site of infection[239]. We therefore decided to investigate 
whether the absence of the signalling molecule IL-4Rα (through which IL-4 and IL-13 signals) 
on keratinocytes in C57BL/6 mice, would result in these resistant mice displaying susceptibility 
during L. major infection. KRT14creIL-4Rα-/lox on a C57BL/6 background were infected 
subcutaneously in the left hind footpad as described above with L. major IL-81 (Figure 2.3A) 
and L. major LV39 (MRHO/SV/59/P strain was used for all experiments from this point 
onwards, replacing the ATTC (MRHO/SU/59/P) strain) (Figure 2.3B). For these infections, 
the littermate (IL-4Rα-/lox) control mice and IL-4Rα-/- were both on C57BL/6 genetic 
backgrounds. Importantly, this is the first report on the use of IL-4Rα-/- on a C57BL/6 genetic 
background in L. major murine models.  Wild-type BALB/c mice were included as a 
susceptible (Th2-driven) control.  Swelling progression in KRT14creIL-4Rα-/lox C57BL/6, 
littermate control mice and IL-4Rα-/- mice were similar during L. major IL-81 infection (Figure 
2.3A). During infection with L. major IL-81, IL-4Rα-/- mice had completely healed by week 6, 
and all mouse groups except wild-type BALB/c mice had completely healed by week 8. 
Similarly, the swelling progression of KRT14creIL-4Rα-/lox C57BL/6, littermate control mice 
and IL-4Rα-/- mice were comparable during L. major LV39 infection (Figure 2.3B). Wild-type 
BALB/c mice had significantly higher swelling compared to littermate control mice (which 
was on a C57BL/6 genetic background) during both L. major IL-81and L. major LV39 
infections. This is expected of the susceptible (wild-type BALB/c) versus resistant background 
(C57BL/6).  
Parasite burdens in the infected footpad, during both L. major IL-81 and L. major LV39 
infections, were similar in KRT14creIL-4Rα-/lox C57BL/6, littermate control mice and IL-4Rα-
/- mice, with a significantly higher burden seen in the wild-type BALB/c mice (Figure 2.3A and 
B). Lymph node parasite burden was similarly low in KRT14creIL-4Rα-/lox C57BL/6, littermate 
control mice and IL-4Rα-/- mice, during both infections, however, during infection with L. 
major LV39, C57BL/6 mice appeared to have a slightly significantly lower burden. As 
expected, wild-type BALB/c mice demonstrated a significantly higher parasite burden during 
both infections as compared to littermate control mice (C57BL/6 genetic background) (Figure 
2.3). During L. major IL-81 infection, C57BL/6 and IL-4Rα-/- mice had no dissemination of the 
parasite to the spleen, while KRT14creIL-4Rα-/lox C57BL/6, littermate control and WT BALB/c 
mice showed dissemination (Figure 2.3A). This was unexpected as KRT14creIL-4Rα-/lox 
C57BL/6 and littermate control, having genetically resistant backgrounds, should have 
behaved like the C57BL/6 mice, and not presented in the spleen. During L. major LV39, only 
WT BALB/c mice displayed dissemination to the spleen, with an outlier in the IL-4Rα-/- mouse 
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group having parasites in the spleen (Figure 2.3B). Collectively, the results indicate that 
deletion of the IL-4Rα on keratinocytes in C57Bl/6 mice does not alter the ability of animals 
to heal lesions, evident in control of footpad swelling and parasite burdens that are comparable 
to littermate control mice.  
 
Figure 2.3 KRT14creIL-4Rα-/lox C57BL/6 mice are clinically resistant to L. major similar to 
littermate control mice in the footpad murine model. Mice were infected subcutaneously in the left 
hind footpad with stationary phase metacyclic L. major promastigotes at either (A) 2 x 105 IL-81 or (B) 
2 x 106 LV39. The change in footpad swelling in mm was measured at weekly intervals (5-7 mice per 
group). Parasite burden was determined at week 6 for (A) and week 8 for (B), by limiting dilution of 
homogenized footpads, single-cell suspensions of the draining popliteal lymph nodes, and homogenised 
spleens. A representative of two individual experiments is shown with mean values ± SEM (Statistical 
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analysis was performed with comparisons to the control IL-4Rα-/lox littermate mice group, as significant 
(*, p˂0.05, **, p˂0.01; ***, p˂0.001). 
 
2.4.5 Cellular and humoral response of KRT14creIL-4Rα-/lox C57BL/6 mice mimics Th1 
immune response similar to resistant C57BL/6 mice during L. major infection in the 
footpad  
To support the phenotypic data observed in KRT14creIL-4Rα-/lox C57BL/6 mice above in Figure 
2.3, we evaluated the immune response of these mice during L. major IL-81 (Figure 2.4) and 
L. major LV39 infection (Figure 2.5) in the footpad. Extracellular staining of lymph node cells 
to show cell populations infiltrating the draining lymph node in KRT14creIL-4Rα-/lox C57BL/6 
mice illustrated that percentages of CD3+CD4+ T helper and CD3+CD8+ T cytotoxic cells were 
similar to those in littermate control mice (Figure 2.4A, Figure 2.5A), as well as in IL-4Rα-/- 
mice and C57BL/6 mice. Wild-type BALB/c mice showed significantly higher percentages of 
CD3+CD4+ T helper and significantly lower CD3+CD8+ T cytotoxic cells compared to the 
littermate control mice. The percentages of the CD19+B220+ B cells in KRT14creIL-4Rα-/lox 
C57BL/6 were similar to littermate control mice, with a significantly higher percentage of B 
cells present in IL-4Rα-/- and C57BL/6 mice (Figure 2.4A, Figure 2.5A). Wild-type BALB/c 
mice showed lower B cell percentages during L. major IL-81 infection (Figure 2.4A), and 
significantly lower B cell levels during L. major LV39 infection (Figure 2.5A) as compared to 
littermate control mice. During L. major IL-81 infection, the percentage of dendritic cells and 
macrophages infiltrating the draining lymph node were similar in all mouse groups (Figure 
2.4B), however, infection with L. major LV39 showed a downregulation of dendritic cells in 
C57BL/6 mice and upregulation of macrophages in wild-type BALB/c mice, with similar levels 
in KRT14creIL-4Rα-/lox C57BL/6, IL-4Rα-/- and littermate control mice (Figure 2.5B).    
CD4+ T cell production of IFN-γ and IL-4 in KRT14creIL-4Rα-/lox C57BL/6 appeared to be 
similar to IL-4Rα-/- and littermate control mice, during both infections, with wild-type BALB/c 
mice showing upregulation in IL-4 during both infections, and an upregulation of IFN-γ during 
L. major LV39 infection (Figure 2.4C, Figure 2.5C). LN re-stimulations with α-CD3 
demonstrated very high levels of IFN-γ in KRT14creIL-4Rα-/lox C57BL/6, IL-4Rα-/-, C57BL/6 
and littermate control mice during L. major IL-81 infection, but only wild-type BALB/c 
showed a significant difference, having lower levels of this cytokine (Figure 2.4D). 
Furthermore, extremely low levels of IL-4 and IL-13 levels were observed after α-CD3-LN 
stimulation in KRT14creIL-4Rα-/lox C57BL/6, IL-4Rα-/-, C57BL/6 and littermate control mice 
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after L. major IL-81 infection,  with  wild-type BALB/c mice showing  significant higher 
production of these two cytokines (Figure 2.4E-F), as previously demonstrated [291]. LN re-
stimulation with SLA after L. major IL-81 infection demonstrated no difference in production 
of cytokines between mouse groups, except for C57BL/6 mice that appeared to produce 
significantly more IL-4 (Figure 2.4E). Re-stimulations of the LN after infection with L. major 
LV39 showed no differences in cytokine production in any of the C57BL/6 background groups, 
however, wild-type BALB/c mice was seen to have produced significantly more IL-4 and IL-
13 after α-CD3-LN stimulation (Figure 2.5D-F). Together, these findings indicate that the IL-
4Rα-responsive keratinocytes are not required to drive a Th1 cellular response during L. major 
infection in the footpad model.   
Infection with L. major IL-81 lead to low titres of SLA-specific Type 1 (IgG2a) and type 2 
(IgG1 and total IgE) antibody titres in KRT14creIL-4Rα-/lox C57BL/6, IL-4Rα-/-, C57BL/6, 
comparable to littermate control mice (Figure 2.4G-I). A highly significant increase in IgG2a, 
IgG1, and total IgE was observed in wild-type BALB/c mice (Figure 2.4G-I) compared to 
littermate controls. We observed the same trends during L. major LV39 infection (Figure 2.5G-
I). Our findings suggest that the humoral responses in KRT14creIL-4Rα-/lox C57BL/6 mice are 
unaffected by the abrogation of IL-4Rα on keratinocytes, during L. major infection in the 
footpad mouse model.  
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Figure 2.4 KRT14creIL-4Rα-/lox C57BL/6 mice develop an immune response similar to littermate 
control and resistant wild-type C57BL/6 mice during L. major IL-81 infection in the footpad 
murine model. At 6 weeks post-infection, mice were sacrificed and popliteal draining lymph nodes 
retrieved. Single cell suspensions obtained from the lymph nodes were extracellularly stained for the 
following populations: (A) T helper (CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); 
(B) dendritic cells (CD11chiMHCIIhi) and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) 
stimulated with PMA/ionomysin/monensin, followed by staining for intracellular cytokine production. 
Cells were re-stimulated with α-CD3 and soluble leishmanial antigen (SLA) for 72 hours, after which 
cytokine production was measured with ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-
specific type 1 (IgG2a) and (H-I) type 2 antibodies (IgG1 and total IgE) were measured in sera from 6 
week infected mice by ELISA. Data is representative of two experiments. Statistical analysis was 
performed with comparisons to the control IL-4Rα-/lox littermate mice group, as significant (*, p˂0.05, 
**, p˂0.01; ***, p˂0.001). 
            
            
            
            





Figure 2.5 KRT14creIL-4Rα-/lox C57BL/6 mice appear to develop a Th1 immune response similar 
to littermate control and resistant wild-type C57BL/6 mice during L. major LV39 infection in the 
footpad murine model. At 8 weeks post-infection, mice were sacrificed and popliteal draining lymph 
nodes retrieved. Single cell suspensions obtained from the lymph nodes were extracellularly stained for 
the following populations: (A) T helper (CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); 
(B) dendritic cells (CD11chiMHCIIhi) and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) 
stimulated with PMA/ionomysin/monensin, followed by staining for intracellular cytokine production. 
Cells were re-stimulated with α-CD3 and soluble leishmanial antigen (SLA) for 72 hours, after which 
cytokine production was measured with ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-
specific type 1 (IgG2a) and (H-I) type 2 antibodies (IgG1 and total IgE) were measured in sera from 6 
week infected mice by ELISA. Data is representative of two experiments. Statistical analysis was 
performed with comparisons to the control IL-4Rα-/lox littermate mice group, as significant (*, p˂0.05, 




2.4.6 Natural route of L. major infection in murine model does not dramatically alter the 
outcome of disease in KRT14creIL-4Rα-/lox mice on both BALB/c and C57BL/6 genetic 
backgrounds. 
While the footpad model for L. major infections in mice is well accepted, recent studies have 
suggested that the ear model may be a better model, providing a more natural mode of infection, 
as it mimics the events that occur during parasite inoculation by the sandfly  [281, 282]. We 
investigated whether a change in site of infection would alter the phenotype and immune 
response of the KRT14creIL-4Rα-/lox. Mice were intradermally infected with a low dose of 
1×104 stationary phase metacyclic L. major IL-81 or L. major LV39 promastigotes, into the 
left ear. As with the footpad infection model, disease progression was monitored during 
infection period, and immune response evaluated after the infection period. 
Ear swelling and disease progression of KRT14creIL-4Rα-/lox BALB/c mice during L. major IL-
81 infection was high, similar to littermate control mice (Figure 2.6A), corresponding to high 
parasite burdens in the ear, lymph node, and spleen (Figure 2.6A). IL-4Rα-/- and C57BL/6 mice 
had significantly lower swelling compared to littermate control mice, with IL-4Rα-/- mice 
appearing to be completely healed by week 8. In the ear, parasite burden was significantly 
lower in IL-4Rα-/- and C57BL/6 mice compared to littermate control mice. C57BL/6 mice also 
showed lower parasite burdens in the draining lymph node and spleen in comparison to 
littermate control (Figure 2.6A). The swelling and parasite burdens in wild-type BALB/c mice 
were similar to littermate control mice. L. major LV39 infection of KRT14creIL-4Rα-/lox 
BALB/c mice resulted in a swelling profile in the ear almost identical to that of the littermate 
control (Figure 2.6B). Interestingly, parasite burden in the ear was significantly lower in all 
mouse groups, including KRT14creIL-4Rα-/lox BALB/c mice, when compared to littermate 
control mice (Figure 2.6B), which was unexpected, and reproducible in both LV39 
experiments. Only IL-4Rα-/- mice showed a significant difference to littermate control mice, in 
burden of parasite in the lymph node, with the remaining mouse groups having similar burdens 
(Figure 2.6B). No parasites were present in the spleens of any of the mouse groups, indicating 
no dissemination to the spleen (Figure 2.6B). Collectively, the data indicates that despite a 
change in site of infection, KRT14creIL-4Rα-/lox BALB/c mice remain susceptible to L. major, 
and remain unaffected by the abrogated IL-4Rα signalling on keratinocytes. Interestingly, with 





Figure 2.6 Cutaneous leishmaniasis is unaffected by the absence of IL-4Rα signalling on 
keratinocytes on a BALB/c genetic background following low-dose L. major infection in the ear 
dermis. Mice were infected intra-dermally in the left ear, with 1 x 104 promastigotes of (A) L. major 
IL-81 or (B) L. major LV39. The change in ear swelling in mm was measured at weekly intervals (5-7 
mice per group). Parasite burden was determined at week 8, by limiting dilution of homogenized ears, 
single-cell suspensions of the draining popliteal lymph nodes, and homogenised spleens. A 
representative of two individual experiments is shown with mean values ± SEM. Statistical analysis 
was performed with comparisons to the control IL-4Rα-/lox littermate mice group, as significant (***, 
p˂0.001). 
 
Cellular immune response of KRT14creIL-4Rα-/lox BALB/c mice in the lymph node remained 
unchanged, similar to littermate control mice, evident in the percentages of T helper, T 
cytotoxic, and B cells (Figure 2.7A), as well as dendritic cells and macrophages (Figure 2.7B), 
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8 weeks after an L. major IL-81 infection. Significant difference in cell population were only 
seen in T helper, responses, where IL-4Rα-/- mice showed higher levels, and C57BL/6 showed 
lower levels of these cells (Figure 2.7A). CD4+ T helper cytokine production (by intracellular 
staining of LN cells), and total cell cytokine production (by LN-re-stimulations), demonstrated 
similar levels of IFN-γ, IL-4 and IL-13 in KRT14creIL-4Rα-/lox BALB/c mice, similar to 
littermate control mice (Figure 2.7C-D). C57BL/6 mice appeared to produce significantly less 
CD4+ T helper IFN-γ and IL-13 as determined by intracellular staining of LN cells (Figure 
2.7C). LN-re-stimulations with α-CD3 illustrated significantly lower IFN-γ in IL-4Rα-/- and 
C57BL/6 mice (Figure 2.7D), and significantly higher IL-4 in wild-type BALB/c mice (Figure 
2.7E).  No differences in antibody titres were observed in the sera of KRT14creIL-4Rα-/lox 
BALB/c mice compared to littermate control mice (Figure 2.7G-I). In comparison to littermate 
controls, IL-4Rα-/- mice had significantly higher levels of SLA-specific IgG2a (Figure 2.7G), 
lower levels of IgG1 (Figure 2.7H), and undetectable levels of IgE (Figure 2.7I). Significantly 
lower levels of IgG1 (Figure 2.7H), and undetectable levels of IgE (Figure 2.7I) was observed 
with C57BL/6 mice compared to littermate controls, after infection with L. major IL-81. 
Together, these results confirm that regardless of the site of infection, IL-4Rα signalling on 
keratinocytes in BALB/c mice do not contribute to T helper responses during L. major IL-81, 





Figure 2.7 Low-dose infection in the ear dermis does not significantly alter immune response of 
KRT14creIL-4Rα-/lox mice on a BALB/c genetic background, demonstrating a similar type 2 
immune response when compared to littermate control mice during L. major IL-81 infection. At 
8 weeks post-infection, mice were sacrificed and popliteal draining lymph nodes retrieved. Single cell 
suspensions obtained from the lymph nodes were extracellularly stained for the following populations: 
(A) T helper (CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); (B) dendritic cells 
(CD11chiMHCIIhi) and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) stimulated with 
PMA/ionomysin/monensin, followed by staining for intracellular cytokine production. Cells were re-
stimulated with α-CD3 and soluble leishmanial antigen (SLA) for 72 hours, after which cytokine 
production was measured with ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-specific type 
1 (IgG2a) and (H-I) type 2 antibodies (IgG1 and total IgE) were measured in sera from 6 week infected 
mice by ELISA. Data is representative of two experiments. Statistical analysis was performed with 
comparisons to the control IL-4Rα-/lox littermate mice group, as significant (*, p˂0.05, **, p˂0.01; ***, 
p˂0.001). 
 
After infection with L. major LV39, the cellular response of KRT14creIL-4Rα-/lox BALB/c mice 
had remained unchanged, in comparison to littermate control mice (Figure 2.8A). This is 
depicted by the percentages of T helper, T cytotoxic, and B cells (Figure 2.8A), as well as 
dendritic cells and macrophages (Figure 2.8B) that remained unchanged in these mice. 
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Significant differences in T helper responses where observed in IL-4Rα-/- and wild-type 
BALB/c mice showing higher levels of these cells, while C57BL/6 showed significantly higher 
levels of T cytotoxic cells (Figure 2.8A). CD4+ T helper cytokine production (by intracellular 
staining of LN cells) and total cell cytokine production (by LN-restimulations) demonstrated 
similar levels of IFN-γ, IL-4 and IL-13 in KRT14creIL-4Rα-/lox BALB/c mice, similar to 
littermate control mice (Figure 2.8C-D). Intracellular staining of LN cells demonstrated 
significantly less IFN-γ, IL-4 and IL-13 produced by the CD4+ T helper of IL-4Rα-/-, C57BL/6 
and wild-type BALB/c mouse groups (Figure 2.8C), compared to littermate controls, further 
confirmed with ELISA detection of α-CD3-LN-re-stimulations (Figure 2.8D-E). In comparison 
to littermate controls, C57BL/6 mice appeared to produce significantly less IL-13 after LN-
restimulations with α-CD3 and SLA (Figure 2.8F). IL-4Rα-/- mice was also seen to have 
produced significantly less IL-13 after LN-restimulations with α-CD3 in comparison to 
littermate control mice (Figure 2.8F). No differences in antibody titres were observed in the 
sera of KRT14creIL-4Rα-/lox BALB/c mice compared to littermate controls after L. major LV39 
infection (Figure 2.8G-I). Wild-type BALB/c and C57BL/6 mice seemed to have significantly 
less titres of SLA-specific IgG2a (Figure 2.8G). Significantly lower levels of IgG1 was 
detected in IL-4Rα-/- and C57BL/6 mice compared to littermate control mice (Figure 2.8H). 
Total IgE was shown to be significantly low in IL-4Rα-/-, C57BL/6 and wild-type BALB/c mice 
in comparison to littermate control mice (Figure 2.8I). These findings confirm that during the 
ear infection, IL-4Rα signalling on keratinocytes in BALB/c mice do not determine the 
dominant T helper response, during L. major LV39, evident in unchanged cellular responses, 












Figure 2.8 Immune response of KRT14creIL-4Rα-/lox mice on a BALB/c genetic background 
remains unaffected with low-dose infection of less virulent L. major LV39 in the ear dermis. At 8 
weeks post-infection, mice were sacrificed and popliteal draining lymph nodes retrieved. Single cell 
suspensions obtained from the lymph nodes were extracellularly stained for the following populations: 
(A) T helper (CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); (B) dendritic cells 
(CD11chiMHCIIhi) and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) stimulated with 
PMA/ionomysin/monensin, followed by staining for intracellular cytokine production. Cells were re-
stimulated with α-CD3 and soluble leishmanial antigen (SLA) for 72 hours, after which cytokine 
production was measured with ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-specific type 
1 (IgG2a) and (H-I) type 2 antibodies (IgG1 and total IgE) were measured in sera from 6 week infected 
mice by ELISA. Data is representative of two experiments. Statistical analysis was performed with 
comparisons to the control IL-4Rα-/lox littermate mice group, as significant (*, p˂0.05, **, p˂0.01; ***, 
p˂0.001).  
As with the footpad infection model, we tested the ear infection model using KRT14creIL-4Rα-
/lox mice on a C57BL/6 genetic background (Figures 2.9-11). Both L. major IL-81 and LV39 
infections resulted in decreased swelling in KRT14creIL-4Rα-/lox C57BL/6, mice IL-4Rα-/- and 
C57BL/6 mice, with significantly higher swelling observed in wild-type BALB/c mice when 
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compared to littermate control mice (Figure 2.9A-B). KRT14creIL-4Rα-/lox C57BL/6 had 
similar parasite burdens to littermate control mice. Ear parasite burdens after both infections 
were significantly lower in IL-4Rα-/-and C57BL/6 mice, while wild-type BALB/c mice showed 
significantly more parasites after the L. major IL-81 infection (Figure 2.9A). Wild-type 
BALB/c mice also showed significantly more parasites in the draining lymph after infection 
with L. major IL-81 (Figure 2.9A) and L. major LV39 (Figure 2.9B), while IL-4Rα-/- and 
C57BL/6 mice only showed significantly less parasites in this organ after infection with L. 
major IL-81 (Figure 2.9A). Parasite dissemination to the spleen did not occur in any of the 
mouse groups, except wild-type BALB/c, mice during either L. major IL-81 (Figure 2.9A) or 
L. major LV39 infection (Figure 2.9B). These results demonstrate that the resistant phenotype 
observed in C57BL/6 mice remains intact even in the absence of IL-4Rα-responsive 








Figure 2.9 L. major phenotype is unaffected by the absence of IL-4Rα signalling on keratinocytes 
on a C57BL/6 genetic background following low-dose L. major infection in the ear dermis. Mice 
were infected intra-dermally in the left ear, with 1 x 104 promastigotes of (A) L. major IL-81 or (B) L. 
major LV39. The change in ear swelling in mm was measured at weekly intervals (5-7 mice per group). 
Parasite burden was determined at week 8, by limiting dilution of homogenized ears, single-cell 
suspensions of the draining popliteal lymph nodes, and homogenised spleens. A representative of two 
individual experiments is shown with mean values ± SEM. Statistical analysis was performed with 
comparisons to the control IL-4Rα-/lox littermate mice group, as significant (***, p˂0.001). 
 
After infection with L. major IL-81, only wild-type BALB/c mice were shown to produce 
significantly more T helper cells in the draining lymph node (Figure 2.10A). There were no 
significant differences in the levels of any of the infiltrating cell populations in the draining 
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lymph nodes of KRT14creIL-4Rα-/lox C57BL/6 mice when compared to littermate control mice 
(Figure 2.10A-B). Intracellular staining of LN cells demonstrated no significant differences in 
CD4+ T helper cytokine production of KRT14creIL-4Rα-/lox C57BL/6 mice as compared to 
littermate control mice (Figure 2.10C). C57BL/6 mice appeared to produce more CD4+ T 
helper IFN-γ, but was not significant, and wild-type BALB/c mice were seen to produce 
significantly more CD4+ T helper IL-4 (Figure 2.10C). Restimulation of LN cells for total cell 
cytokine production, demonstrated no significant differences in the cytokine production of 
KRT14creIL-4Rα-/lox C57BL/6 mice as compared to littermate control mice (Figure 2.10D-F). 
After LN re-stimulations with α-CD3, IL-4Rα-/- and C57BL/6 mice produced significantly less 
IFN-γ (Figure 2.10D). Wild-type BALB/c mice were shown to produce significantly more IL-
4 (Figure 2.10E) and IL-13 (Figure 2.10F) after α-CD3 LN re-stimulations. After infection with 
L. major IL-81, SLA-specific Type 1 (IgG2a) and type 2 (IgG1 and IgE) antibody titres in 
KRT14creIL-4Rα-/lox C57BL/6, IL-4Rα-/-, C57BL/6 and littermate control mice showed 
similarly low to no levels of each antibody, with a highly significant increase in IgG2a, IgG1, 
and IgE observed in WT BALB/c mice (Figure 2.10G-I). Collectively, the data confirms 
observations made in the footpad model. During an ear infection with L. major IL-81, 
abrogation of IL-4Rα-signalling on keratinocytes in C57BL/6 mice does not render these mice 
susceptible, as postulated. This was evident in control of ear swelling, cellular infiltration in 
the LN as well as cellular and humoral immunity. 
Following L. major LV39 infection, extracellular staining on isolated draining lymph nodes 
showed no significant differences in cell populations of KRT14creIL-4Rα-/lox C57BL/6 mice 
(Figure 2.11A-B) compared to littermate controls, with IL-4Rα-/- and wild-type BALB/c mice 
producing significantly more T helper cells and significantly less B cells (Figure 2.11A). 
Intracellular staining of LN cells showed no significant differences in CD4+ T helper cytokine 
production of KRT14creIL-4Rα-/lox C57BL/6 mice (Figure 2.11C) in comparison to littermate 
controls, while wild-type BALB/c mice produced significantly more CD4+ T helper IL-4 
(Figure 2.11C). After LN re-stimulations with α-CD3 and SLA, total cell cytokine production 
of KRT14creIL-4Rα-/lox C57BL/6 LN cells remained similar to littermate control (Figure 2.11D-
F), while IFN-γ was significantly decreased in IL-4Rα-/- mice (Figure 2.11D), and IL-4 as well 
as IL-13 were significantly increased in wild-type BALB/c (Figure 2.11E-F). SLA-specific 
Type 1 (IgG2a) and type 2 (IgG1 and total IgE) antibody titres in KRT14creIL-4Rα-/lox 
C57BL/6, IL-4Rα-/-, C57BL/6 and littermate control mice showed similarly low to no levels of 
each antibody, with a highly significant increase in IgG2a, IgG1, and total IgE observed in 
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wild-type BALB/c mice after L. major LV39 infection  (Figure 2.11G-I). Together, these 
findings confirm, that in C57BL/6 mice, IL-4Rα-responsive keratinocytes do not contribute to 
protective responses during L. major infection in the ear, as illustrated by unaltered cellular 
responses, cytokine production and humoral responses. 
Figure 2.10 A similar type 1 immune response is observed in KRT14creIL-4Rα-/lox mice on a 
C57BL/6 genetic background following low-dose infection in the ear dermis during L. major IL-
81 infection. At 8 weeks post-infection, mice were sacrificed and popliteal draining lymph nodes 
retrieved. Single cell suspensions obtained from the lymph nodes were extracellularly stained for the 
following populations: (A) T helper (CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); (B) 
dendritic cells (CD11chiMHCIIhi) and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) stimulated 
with PMA/ionomysin/monensin, followed by staining for intracellular cytokine production. Cells were 
re-stimulated with α-CD3 and soluble leishmanial antigen (SLA) for 72 hours, after which cytokine 
production was measured with ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-specific type 
1 (IgG2a) and (H-I) type 2 antibodies (IgG1 and IgE) were measured in sera from 6 week infected mice 
by ELISA. Data is representative of two experiments. Statistical analysis was performed with 





Figure 2.11 Lower virulence of L. major LV39 does not appears to alter the type 1 immune 
response observed in KRT14creIL-4Rα-/lox mice on a C57BL/6 genetic background similar to 
littermate control mice, following low-dose infection in the ear dermis. At 8 weeks post-infection, 
mice were sacrificed and popliteal draining lymph nodes retrieved. Single cell suspensions obtained 
from the lymph nodes were extracellularly stained for the following populations: (A) T helper 
(CD3+CD4+), T cytotoxic (CD3+CD8+), B cells (CD19+B220+); (B) dendritic cells 
(CD11chiMHCIIhi) and macrophages (CD11bhiCD11c-MHCIIhi), and also (C) stimulated with 
PMA/ionomysin/monensin, followed by staining for intracellular cytokine production. Cells were re-
stimulated with α-CD3 and soluble leishmanial antigen (SLA) for 72 hours, after which cytokine 
production was measured with ELISA for (D) IFN-γ, (E) IL-4 and (F) IL-13. (G) L. major-specific type 
1 (IgG2a) and (H-I) type 2 antibodies (IgG1 and total IgE) were measured in sera from 6 week infected 
mice by ELISA. Data is representative of two experiments. Statistical analysis was performed with 




L. major is the most studied strain of the leishmania parasites [293], and mouse models for this 
disease has been well studied, both in our laboratory [94, 132, 135, 294] as well as in other 
groups [285-287]. The outcome of L. major infection is dependent on the development of a 
57 
 
polarized Th1 or Th2 response that is associated with resistance or susceptibility, respectively 
[176]. IL-4 has long been considered as a characteristic Th2 driving cytokine in susceptible 
BALB/c mice during L. major infection [78, 176, 179, 182, 295, 296]. Kopf et al. showed that 
disrupting the IL-4 gene in BALB/c mice resulted in these generally susceptible mice, to 
become resistant to L. major infection [179]. In contrast, Stager et al. demonstrated that 
BALB/c mice with a deletion for IL-4 or IL-4Rα were more susceptible during L. donovani 
infection compared to wild-type BALB/c mice, indicating a role for protection for IL-4, IL-13 
and IL-4Rα in protection with in the L. donovani model. More recent studies have demonstrated 
a role for IL-4 in driving a polarised Th1 response, usually evident in genetically resistant 
C57BL/6 mice during infection with L. major [235, 291]. One of the pivotal studies was 
performed by Biedermann et al. through in vitro and in vivo experiments [235]. Here, the 
authors generated dendritic cells from bone-marrow cells they derived from the femurs and 
tibias of BALB/c mice, and incubated them with a synthetic immune-stimulatory oligomer 
(CpG DNA), in the presence or absence of recombinant IL-4 at a concentration of 103 U/ml. 
After IL-4 stimulation, they quantified the IL-12 present in the supernatant, using ELISA 
techniques, and found higher IL-12 production in the IL-4-treated sample. They next primed 
ovalbumin-specific CD4+ T cells with the previously CpG DNA+IL-4- or  CpG DNA-IL-4- 
activated dendritic cells, and after a week, restimulated them with fresh APCs. IFN-γ was 
significantly upregulated when T cells were primed with dendritic cells that had been 
previously activated with CpG DNA and IL-4. Conversely, serum IFN-γ was significantly 
downregulated while IL-4 was upregulated when IL-4 was present during the priming of T 
cells. Together, these findings indicated that IL-4 could induce the production of IL-12 by 
APCs, and additionally, demonstrated that the Th2 characteristic IL-4 could in fact instruct 
dendritic cells to express a Th1-inducing phenotype  [235]. Dendritic cells are the primary 
source of IL-12, and initiates antigen-specific immunity to Leishmania [212]. Biedermann et 
al. supplemented the in vitro findings data with in vivo mouse experiments, showing that mice 
treated with 1 µg of recombinant IL-4 within the first 8 hours of infection, displayed 
significantly decreased swelling of the footpad and lesion, evident of a resistant phenotype. 
The authors found, however, that when they treated mice with a lower concentration of IL-4, 
or if treatment was much later, after 12 hours, it resulted in decreased production of IFN-γ, and 
an increase in the production of IL-4. Their findings suggested that early IL-4 was required to 
drive dendritic cells to elicit a Th1 response. From these observations, Biedermann et al. 
developed the principle of the “IL-4 instruction theory”. This study did, however, raise a 
question of the importance of biological quantities of IL-4, and the effect this had on the 
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immune response. Recently published work by Hurdayal et al. from our laboratory [135], 
addressed this, using BALB/c mice with abrogated IL-4Rα on dendritic cells, and illustrated 
that during L. major infection, these mice displayed hyper susceptibility to infection. This was 
evident in significantly increased swelling and parasite burdens, in addition to increased 
production of Th2 cytokines and type 2 antibodies. These finding further supported the findings 
reported by Biedermann et al. [235]. Following the theory, that early stage IL-4 is key in 
dendritic cell-driven Th1 immunity, Ehrchen et al. carried out experiments to further explore 
this, by focusing on the early stages of infection, looking at the initial infected site, specifically 
the microenvironment of the infected tissue [239]. The authors infected BALB/c and C57BL/6 
mice in the footpad with L. major and screened for gene expression patterns using microarray 
analysis. In both mouse backgrounds, they found 189 genes that were significantly upregulated, 
and 16 genes that were down-regulated. For a more sensitive analysis, PCR was performed on 
skin samples, demonstrating an upregulation of chemokines, and the presence of cytokines (IL-
12, TNF-α, IL-4, and IL-6), that were found to be more strongly induced in C57BL/6 mice 
compared to BALB/c mice [239]. Functional clustering indicated an overrepresentation of 
genes involved in inflammatory responses, chemotaxis, and cytokines, in the groups of genes 
that were found to be upregulated in both BALB/c and C57BL/6 mice, with some genes more 
highly regulated in the C57BL/6 mice. Additionally, genes that are involved in keratinocyte 
differentiation were also found to be overrepresented, suggesting an influence on their 
expression by the presence of L. major parasites. The authors next performed laser 
microdissection of the epidermal keratinocytes from skin, 16 hours after L. major infection, 
and applied the in-situ hybridization technique, followed by real-time PCR (RT-PCR). They 
showed a list of immune mediators that were induced, including IL-4, TNFα, IL-12 and IL-6, 
and illustrated cytokine induction by the skin and keratinocytes were higher in C57BL/6 mice. 
What this also meant, was that keratinocytes appeared to be a significant source of both early 
and particularly expressed genes in L. major infected footpads [239]. While Biedermann et al., 
showed that exogenous recombinant IL-4 could drive dendritic cells to instruct a Th1 response 
[235], Ehrchen and his group set out to illustrate the role of local endogenous IL-4, by blocking 
the endogenous IL-4 with exogenous anti-IL-4 antibody. Here, the authors carried out L. major 
infections in C57BL/6 mice, where, at the time of infection with L. major parasites into the 
footpad, 1 mg neutralizing rat anti-mouse IL-4 antibody or irrelevant rat IgG neutralizing was 
also injected, followed by a second treatment with antibody 4 hours later. A week later, analysis 
of L. major antigen-specific CD4+ cytokine secretion illustrated significantly increased 
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quantities of IL-4 and IL-13, and significantly decreased IFN-γ. This indicated a switch in these 
genetically resistant C57BL/6 mice to a Th2 phenotype [235]. 
Essentially, two important ideas are introduced. Firstly, keratinocytes appear to be highly 
activated by L. major parasites, and in response, secretes chemokines and cytokines, one of 
which is IL-4, which is upregulated in genetically resistant C57BL/6 mice [239]. Secondly, IL-
4 can instruct dendritic cells to produce Th1 cytokines and cause a shift towards a Th1 immune 
response [235, 239]. As mentioned previously, in addition to IL-4, IL-13 also signals via IL-
4Rα [98]. Most studies have shown that IL-13 plays a role in susceptibility to L. major [291, 
297], and L. mexicana infection [298]. Mohrs et al., however, showed that IL-13 can have a 
protective role during chronic cutaneous leishmaniasis, and this is dependent on signalling via 
the IL-13 receptor [233]. During the study by Ehrchen et al., IL-13 expression was not found 
to be significant factor. Keratinocytes can, however, signal and secrete IL-13 [64, 67]. 
Following on from the studies by Biedermann et al. [235] and Ehrchen et al. [239], we aimed 
to investigate whether IL-4Rα on keratinocytes, and the IL-4/IL-13 signalling via this receptor, 
plays a role in disease outcome during cutaneous leishmaniasis. If IL-4Rα is indeed 
demonstrated to be important for disease outcome, this would suggest that the IL-4/IL-13 
released by these keratinocytes could signal and influence keratinocytes, in an autocrine 
manner, or influence dendritic cells in a paracrine manner. The autocrine/paracrine tendency 
of keratinocytes has been illustrated during atopic dermatitis [299]. Here, Yoon et al. showed 
that endogenous toll-like receptor 4 induced keratinocytes to secrete IL-23, which, in a 
paracrine manner, influences dendritic cells to drive production of IL-22 [299], which is 
important for antibacterial functions [300-302], keratinocyte proliferation (autocrine) and 
epidermal thickening [303, 304]. To address our abovementioned hypothesis, our laboratory 
generated a keratinocyte-specific IL-4Rα knock-out mouse model using the Cre/loxP system 
under the control of the K14 promotor. The use of these mice in L. major infection models, in 
addition to cell based assays, allowed us to evaluate disease progression and outcome, in the 
absence of IL-4Rα-responsive keratinocytes.  
The footpad mouse model in L. major, is well accepted and widely used [94, 132, 135, 233, 
284, 305-307], as the clinical progression of disease can be evaluated by simply measuring the 
swelling of the footpad, and the subcutaneous route of infection causes a more potent immune 
response, compared to intradermal infections [308]. Additionally, when the subcutaneous route 
was compared to an intradermal route, during L. donovani infection in BALB/c mice, the 
subcutaneous inoculation elicited a more potent Th1 responses [309]. Infection of KRT14creIL-
4Rα-/lox BALB/c mice in the footpad with L. major IL-81 or LV39 revealed no role for IL-4Rα-
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responsive keratinocytes in modulating disease outcome. KRT14creIL-4Rα-/lox BALB/c mice 
presented as susceptible mice, as evident in increased swelling and parasite burdens, which is 
characteristic of genetically susceptible BALB/c mice [293]. While global IL-4Rα-/- BALB/c 
mice were resistant to L. major IL-81 as shown by Hurdayal et al. and Radwanska et al. [310], 
these mice appeared to be susceptible to L. major LV39 infection, contradictory to observations 
made by previous studies in the laboratory [94, 132, 135, 233, 234] with this strain. This 
contradictory finding is, however, not entirely unusual, as susceptibility to L. major LV39 by 
global IL-4Rα-/- BALB/c has been demonstrated in early studies by Noben-Trauth et al. [291]. 
This difference in disease outcome observed here is due to the difference in the source and sub 
strain of the L. major LV39. While the infections in mice on BALB/c genetic background, in 
the footpad model in our study used the LV39 sub strain sourced from ATTC, subsequent 
infections used the LV39 sub strain sourced from the University of Lausanne. Additionally, 
Hurdayal et al. and Radwanska et al. [132, 135] used sub strains from Mattner et al. [180]. 
Furthermore, Kebaier et al. also demonstrated that different isolates of L. major parasite strains 
can differ in virulence, thus varying the influence the strain has on the course of disease it 
elicits in mouse models [288]. KRT14creIL-4Rα-/lox BALB/c showed dissemination of parasites 
to the spleen similar to littermate control mice, similar to wild-type BALB/c mice, after L. 
major infection, which is expected in susceptible wild-type BALB/c mice [182, 311]. In these 
mice, the mounting of a Th2 response, along with alternative activation of macrophages, is the 
reason why parasites disseminate and cause severe disease [211, 312-314]. The parasites can 
use the polyamines generated from alternative activation for their growth and survival [135]. 
The presence of L. major parasites in the spleens of global IL-4Rα-/- BALB/c and C57BL/6 is 
not entirely unexpected, as patchwork mutation (PWK) mice, that are self-healing, and able to 
control parasite multiplication, have demonstrated visceral dissemination of the parasites [312]. 
Disease progression in BALB/c mice infected with L. major corresponds to an upregulation 
Th2 cytokines, CD4+ Th2 cells, and type 2 antibody responses [132, 135, 234, 295, 297, 315]. 
Resistant C57BL/6 had significantly less T helper cells. CD4+ T helper and CD8+ T cytotoxic 
responses are important for an effective Th1 immune response to be mounted as well as 
resolution of the disease [174, 293, 316]. C57BL/6 mice appeared to have decreased CD4+ Th 
cells, which may have been due to the evaluation being made at the end of the infection period, 
when initial immune response have already been established. Increased infiltration of 
macrophages to the draining lymph node in C57BL/6 mice, could be linked to the roles they 
play in protection, being important not just for uptake of parasites and establishment of an 
immune response, but also for their killing function by classically activated macrophages [174, 
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177, 205, 206, 237]. Our intracellular staining panel did not include markers for iNOS and Arg, 
to indicate the presence of classically or alternatively activated macrophages in the mouse 
groups, however, we could assume KRT14creIL-4Rα-/lox BALB/c mice may have shown higher 
frequencies of alternatively activated macrophages, as they were susceptible to L. major 
infection [134, 208, 315, 317]. CD4+ T cell production of cytokines, illustrated both Th1 (IFN-
γ) and Th2 cytokines (IL-4 and IL-13) in KRT14creIL-4Rα-/lox BALB/c mice, instead of a 
polarised Th2 response as expected of susceptible wild-type BALB/c mice [176, 318]. This 
phenomenon of a mixed response has been observed in wild-type BALB/c mice infected with 
L. infantum [319].  C57BL/6 demonstrated a significant upregulation of IFN-γ, while IL-4 and 
IL-13 were significantly downregulated, indicative of a clear Th1 polarisation for a resistant 
phenotype [174, 176, 209, 318]. Clinically resistant global IL-4Rα-/- BALB/c mice also showed 
a downregulation of IL-13, similar to recent publications [94, 132, 135, 234, 320]. Compared 
to intracellular staining, which measures only CD4+ T cell production of cytokines, ELISA 
evaluation provides an indication of total cytokine production by total lymph node cells. 
KRT14creIL-4Rα-/lox BALB/c mice produced both Th1 (IFN-γ) and Th2 cytokines (IL-4 and 
IL-13) at similar levels, similar to above. Despite their healing phenotype, C57BL/6 mice had 
downregulated IFN-γ produced by various lymph node cells and significantly lower quantities 
of IL-4 and IL-13. Similarly, Anderson and colleagues recently showed that while C57BL/6 
infected with L. major mounted a Th1 polarised immune response as expected, these mice did 
not heal their lesions [321]. This highlights the fact that the level of IFN-γ-secreting cells does 
not necessarily, or in all cases, reflect a healing response. Resistant global IL-4Rα-/- BALB/c 
mice also had downregulated levels of IL-4 and IL-13 similar to previous studies [135, 233]. 
KRT14creIL-4Rα-/lox BALB/c produced Type 1 and 2 antibodies. Susceptible strains such as 
wild-type BALB/c mice, have been shown in early studies to produce lower levels of IgG2a 
and higher levels of the Type 2 antibodies IgG1 and total IgE [233, 322]. IgG1 is linked to 
progressive leishmaniasis, with this antibody being associated with an increase in lesion 
thickness in WT BALB/c mice [323]. While KRT14creIL-4Rα-/lox BALB/c mice did develop 
progressive swelling and lesions, these mice had fairly low levels of IgG1. Global IL-4Rα-/- 
BALB/c and C57BL/6 mice showed extremely low to no levels of IgG1 and IgE, indicative of 
their inability to class switch. Together, the data suggested that BALB/c mice with abrogated 
IL-4Rα were susceptible to L. major infection and did not develop a polarised T helper 
response. Furthermore, the data indicated that in BALB/c mice, IL-4Rα on keratinocytes did 
not play a role in protection.  
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 As mentioned earlier, previous studies suggest keratinocytes as the source of IL-4 to instruct 
dendritic cells to mount a Th1 polarised response [239]. Ehrchen et al. [239] showed that 
genetically resistant C57BL/6 mice appear to have significantly high levels of IL-4 secreted by 
keratinocytes, and the early local neutralization of the IL-4 resulted in susceptibility to L. major 
infection. We therefore tested our hypothesis using the KRT14creIL-4Rα-/lox on a C57BL/6 
genetic background. For these experiments, IL-4Rα-/- was also on a C57BL/6 genetic 
background, which is, to our knowledge, the first time the use of these mice has been reported.  
KRT14creIL-4Rα-/lox C57BL/6 mice behaved like littermate control mice, developing low 
swelling, and healed lesions by week 8 of L. major LV39 infection. During these L. major 
LV39 infections, KRT14creIL-4Rα-/lox C57BL/6 mice showed low parasite loads in the footpad, 
draining lymph node and spleen, similar levels of infiltrating cells, and the predominant 
production of IFN-γ, with lesser quantities of IL-4 and IL-13, similar to littermate controls (on 
the same C57BL/6 background). Antibody levels were unchanged, with low levels of type 1 
and type 2 antibodies observed, corresponding to antibody profiles of C57BL/6 mice in 
previous studies [135, 233]. Interestingly, during both L. major IL-81 and LV39 infections, IL-
4Rα-/- C57BL/6 mice completely healed at the end of the infection period. These mice also 
showed significantly higher levels of B cells similar to C57BL/6 mice with both strains of L. 
major, which could not be explained. B cells have been shown to contribute to susceptibility 
to L. major infection [232, 324, 325]. Additionally, a recent study from our laboratory has 
indicated a role for IL-4Rα-responsive-B cells in susceptibility to L. major infection 
(Unpublished). Essentially, KRT14creIL-4Rα-/lox C57BL/6 were resistant, as expected of a 
C57BL/6 mouse. Together, these results suggested that if early IL-4 is instructing resistance to 
L. major infection as previously demonstrated [135, 235], it did not appear that the early IL-4 
was in fact signalling through the IL-4Rα on keratinocytes.  
An alternative to the subcutaneous footpad infection model, is an intradermal inoculation of 
low dose metacyclic promastigote L. major parasites (10-1000 parasites) in the ear, a site of 
infection that is becoming more favoured, as it better mimics natural infection by the sandfly, 
and is better at reproducing the natural lesion formed [281-283, 326-329]. KRT14creIL-4Rα-/lox 
BALB/c mice behaved similar to littermate controls, seen in swelling progression and parasite 
burden. During L. major LV39 infection, these mice showed significantly less parasites at the 
site of infection (the ear), similar to observations by Parihar et al. [283]. This suggests that 
these mice were able to control parasite replication in the ear. This could be attributed to iNOS-
secreting macrophages and recently described, iNOS-secreting dendritic cells, shown to control 
intracellular parasitism [315, 330]. Global IL-4Rα-/- BALB/c mice completely healed lesions 
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caused by L. major IL-81 and had increased swelling progression during L. major LV39 as 
seen above. Dissemination of parasites was seen in all mouse groups, only after L. major IL-
81 infection. This strain is highly virulent, and as mentioned above, visceral dissemination of 
L. major parasites has been shown [135, 312]. Cellular and humoral responses of KRT14creIL-
4Rα-/lox BALB/c mice after infection with L. major IL-81, remained unchanged similar to 
littermate controls, as above. As observed in the footpad infection model, global IL-4Rα-/- 
BALB/c mice had upregulated T helper responses, while C57BL/6 had downregulated T helper 
cells. Both C57BL/6 and IL-4Rα-/- BALB/c mice had decreased IFN-γ, similar to findings with 
the footpad infection model. As expected C57BL/6 mice showed decreased IL-13, while wild-
type BALB/c mice had increased IL-4.  Antibody responses of IL-4Rα-/- BALB/c and C57BL/6 
mice correlated with the expected antibody profile of a resistant mouse. Infection with L. major 
LV39 saw no change in immune response of KRT14creIL-4Rα-/lox BALB/c mice. Together, our 
data suggested that while IL-4Rα-responsive keratinocytes were not contributing to the overall 
T helper immune responses of KRT14creIL-4Rα-/lox BALB/c mice in the ear infection model, 
parasite replication at the site of infection appeared to be more controlled in these mice, in 
comparison to littermate controls. KRT14creIL-4Rα-/lox C57BL/6 mice infected with L. major 
had swelling and disease similar to littermate controls. With these experiments, global IL-4Rα-
/- C57BL/6 mice completely healed their lesions during L. major IL-81, as above, also showed 
resistance to L. major LV39, similar to C57BL/6 mice. This, again, highlights the importance 
of the source of the sub-strain, as explained above. Wild-type BALB/c mice had upregulated 
T helper cells, IL-4, and IL-13 after infection with L. major IL-81, as expected. KRT14creIL-
4Rα-/lox C57BL/6 infected with L. major produced both Th1 and Th2 cytokines, however, 
unlike KRT14creIL-4Rα-/lox BALB/c mice, these mice did appear to have a more polarised Th1 
cytokine production as expected of this genetic background. Together, these results indicate 
that IL-4Rα signalling on keratinocytes in C57BL/6 mice is not required for protection against 
L. major infection in the ear.  
It would seem that the IL-4Rα-responsive keratinocytes may not be contributing to the early-
IL-4-driven polarised Th1 response as suggested by Ehrchen et al. [239]. The question then 
remains, as to which of the many cell types that signal and secrete IL-4/IL-13 (highlighted in 
Chapter 1), could be contributing to this shift in the response during L. major infection. 
Neutrophils are the first cells to be recruited to the infection site, and can signal IL-4/IL-13 
through the IL-4Rα [331]. While some studies have indicated a role for neutrophils in 
susceptibility to L. major infection [196, 237], others have shown their contribution to 
resistance to L. major [332, 333]. Alternatively, mast cells, that are also capable of signalling 
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and secreting IL-4/IL-13 through IL-4Rα [334], could be the determining factor in the early-
IL-4-driven polarised immune response to L. major. Mast cells can be found in the skin layer 
and contribute to the hosts’ defence mechanisms [335]. Furthermore, as with neutrophils, they 
are one of the first cell types to have contact with the Leishmania parasite during infection 
[336]. These cells are also capable of producing nitric oxide [337], in addition to pro-
inflammatory molecules that are stored within the granules found in the cytoplasm, and can be 
released within minutes of activation [338]. Mast cells release cytokines, including Th1 IFN-γ 
and TNF-α, and Th2 IL-4 and IL-10, during Leishmania infection, which can influence the 
immune response [339]. While degranulation of mast cells has been shown to contribute to 
susceptibility to L. major infection [340], Mauer et al. demonstrated a role for these cells in 
protection against L. major infection [341]. Using mast cell-deficient Kit(W)/Kit(W-v), Mauer 
et al. showed that during L. major infection, these  mice developed significantly larger skin 
lesions than control mice, and when these mice were cutaneously reconstituted with mast cells, 
it normalized the development of lesions [341]. Furthermore, these Kit(W)/Kit(W-v) mice had 
significantly higher parasite burdens showed dissemination of parasites to the spleen, in 
comparison to control mice. Additionally, the recruitment of neutrophils and macrophages 
appeared to be dependent on the mast cells. Importantly, the recruitment of dendritic cells 
seemed to be heavily dependent on mast cells [341]. These findings provide sufficient evidence 
to suggest a possible role for mast cells in contributing to the IL-4-driven dendritic cell Th1 
polarised response seen by Ehrchen et al. [239].  
2.6 Conclusion  
Our results illustrate that the abrogation of IL-4/IL-13 signalling via IL-4Rα on keratinocytes 
results in a non-polarised immune response in BALB/c mice, but does not affect their non-
healing phenotype. In these mice, however, the absence of IL-4Rα-responsive keratinocytes 
does contribute to parasite control at the site of infection, in the ear model. We showed that the 
loss of IL-4/IL-13, signalling via IL-4Rα on keratinocytes in C57BL/6 mice, does not alter the 
overall polarised Th1 response, or the healing phenotype. We have also shown, as have others, 
that a difference sub-strains/sources of L. major parasite can alter the immune response 
differently. Lastly, we have reported immune responses in global IL-4Rα-/- C57BL/6 mice, 
during L. major infection for the first time. These mice remain resistant to infection, and 
compared to IL-4Rα-/- BALB/c mice, have dampened antibody responses. 
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Chapter 3 IL-4Rα–responsive keratinocytes are not required for control during acute 
schistosomiasis in mice 
3.1 Introduction 
Schistosomiasis is a neglected tropical parasite disease caused by blood flukes, the trematode 
flatworms, belonging to the Schistosoma genus. The disease affects approximately 200 million 
people each year, and is endemic in 52 countries across the globe [240, 241]. The life cycle of 
Schistosoma mansoni (S. mansoni)  begins when infective cercariae penetrate the skin of the 
host and transform into schistosomula that migrate to peripheral vessels [342, 343]. 
Schistosomula mature to adult worms and lay eggs in the mesenteric venules. Some of the eggs 
are excreted in faeces, while others are shunted via the hepatic portal vein into the liver where 
they become trapped. The trapped eggs induce a T helper 2 (Th2) immune response that drives 
granuloma formation and tissue fibrosis, the key pathological features of schistosomiasis [134, 
265, 266]. While there have been studies showing that cercariae can affect the function of 
dermal and epidermal cells [344-346], there have been very few studies investigating epidermal 
keratinocytes and their role during schistosomiasis [278, 279].  
Keratinocytes make up a large part of the epidermal cellular population. These cells contribute 
to epidermal cytokine production, which influences the migration of inflammatory cells and 
can have systemic effects on the immune system [67]. The importance of epidermal 
keratinocytes as a physical barrier is well known [39]. However, their role in immunological 
defence is poorly understood. Recent studies have shown that keratinocytes can produce 
growth factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte 
macrophage colony-stimulating factor (GM-CSF), and cytokines such as tumour necrosis 
factor alpha (TNF-α); IL-3; IL-6 and IL-8 [53, 55, 59, 60, 67, 347]. Moreover, keratinocytes 
have been shown to play a key role in skin-related diseases such atopic dermatitis and psoriasis, 
where these cells contribute to pathogenesis [54, 348, 349].  
Murine models of schistosomiasis have played an important role in providing a better 
understanding of the elicited host immune responses, and defined a host-protective role for 
signalling through the IL-4 receptor α chain (IL-4Rα) [130, 134, 136, 277]. A recent study by 
Ehrchen et al. postulated that IL-4 from keratinocytes drives a Th1 immune responses during 
Leishmania major (L. major) infection  [239]. Considering the protective role that IL-4/IL-13 
and IL-4Rα play during acute schistosomiasis, we postulated that IL-4Rα-responsive 
keratinocytes are crucial for host protection during S. mansoni infection.  
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In order to investigate the role of IL-4Rα-responsive keratinocytes, we generated a 
keratinocyte-specific IL-4Rα-deficient BALB/c mouse (KRT14creIL4Rα-/lox), using the 
Cre/loxP recombination system. These mice were infected with S. mansoni cercariae to 
evaluate their survival, organ pathology, and the immune responses elicited. We found that 
KRT14creIL4Rα-/lox mice were susceptible to acute schistosomiasis, similar to littermate 
controls. KRT14creIL4Rα-/lox mice developed sufficient Th2 immune responses as seen by T 
helper cytokines, type 2 antibodies, and B cell cytokines.  Together, our findings suggest that 
IL-4Rα-responsive keratinocytes are not required for control of acute schistosomiasis in mice.  
3.2 Materials 
All general reagents were purchased from either of the following suppliers: Merck Chemicals 
(Pty) Ltd.; Gibco Life Technologies; Invitrogen Life Technologies and Sigma Aldrich. 
Molecular biology reagents were purchased from ThermoScientific, BD Biosciences and 
Fermentas Life Sciences. Buffers and reagents are listed in the Appendix.   
3.3 Methods 
3.3.1 Ethical statement 
All mouse experiments and protocols were performed in strict accordance with the South 
African national guidelines, as well as the Animal Research Ethics Committee of the Faculty 
of Health Sciences, University of Cape Town (license no. 014/003). All effort were made to 
minimise and reduce suffering of animals. 
3.3.2 Generation of KRT14creIL-4Rα-/lox mice 
Keratinocyte cell-specific IL-4Rα-deficient (KRT14creIL4Rα-/lox) BALB/c mice were 
generated using the Cre/loxP system, and characterized in our laboratory (Supplementary 
Figure). Briefly, KRT14cre mice (Jackson laboratory) were crossed with IL-4Rα-/- BALB/c 
mice [233] and transgenic IL-4Rαlox/lox mice [134] to generate hemizygous KRT14creIL-4Rα-
/lox BALB/c mice. All mice were kept under specific pathogen-free conditions in individually 
ventilated cages. Experimental mice were age and sex matched.  
3.3.3 Live S. mansoni infection 
Mice were percutaneously infected with 100 live cercariae (7 week acute infection) or with 80 
live cercariae (12 week mortality study). Snails were provided by the Schistosome Research 
Reagent Resource Center for distribution by BEI Resources, NIAID, NIH: Schistosoma 
mansoni, Strain NMRI Exposed Biomphalaria glabrata, Strain NMRI, NR-21962. 
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3.3.4 Isolation and ex vivo stimulation of draining lymph node cells 
Single cell suspensions were prepared by pressing the draining mesenteric lymph nodes (MLN) 
through cell-strainers (70 μM followed by 40 μM). Cells were re-suspended in complete IMDM 
supplemented with 10% FCS and an antibiotic mix (penicillin and streptomycin at 100 U/ml 
each). Cells were cultured at 2 × 106 cells/ml in 96-well NUNC® plates coated with α-CD3 at 
20 μg/ml or in the presence of  SEA (20 μg/ml) and incubated at 37ºC in a humidified incubator 
containing 5% CO2. Supernatants were collected after 72 h and cytokines were measured by 
ELISA. The following cytokines were measured by sandwich ELISA: IL-4, IL-5, IL-6, IL-10, 
IL-13, IFN-γ and IL-17, as previously described [233] 
3.3.5 Flow cytometry 
MLN cells from S. mansoni infected mice were prepared as previously described (Section 
3.3.4) and seeded (1×106 cells per well) for extracellular staining to analyse cellular 
populations. Briefly, cells were stained with 50 μl antibody mix for 30 min at 4°C. After 
incubation, 150 μl FACS buffer was added and cells were centrifuged at 5 000 × g for 5 min at 
4°C. The pellet was resuspended in 200 μl FACS buffer. The following panel was set up to 
stain for CD4+ T: CD3-Alexa700; CD4-PerCP; CD44-FITC; CD62L-APC. The B cell panel 
included: B220-V500; CD19-PerCpCy5.5; CD23-PE, and CD21-APC. Dendritic cell and 
macrophage panel included:  CD11c-APC; CD11b- V450; MHCII- Alexa700. Each mix also 
included 1% rat serum and 10 µg FcγR blocker (Fcγ). 
For intracellular cytokine (IC) staining, cells were seeded (2×106 cells per well) in 96 well U-
bottom plates and stimulated with 50 ng/ml phorbal myristate acetate (PMA) and 250 ng/ml 
ionomycin in the presence of 200 μM monensin for 6 h. Following surface staining in 50 μl 
antibody mix (CD3-Alexa700, CD4-V500, CD19-PerCP-Cy5.5) for 30 min at 4°C, cells were 
washed and fixed with 2% paraformaldehyde (PFA) for 30 min in the dark, and permeabilized 
with 0.1% (m/v) saponin buffer for 30 min. Intracellular cytokines were added for 60 min at 
4°C, followed by a wash and final re-suspension in FACS buffer, ready for acquisition. The IC 
panel contained the following antibodies: IFN-γ-APC; IL-4-PE; IL-10-FITC and IL-13-PeCy7. 
Acquisition of cells was performed on the Fortessa machine (BD, San Jose, CA, USA). Flow 
data was analyzed using Flowjo software (Treestar, Ashland, OR, USA). 
3.3.6 Enzyme Linked Immunosorbent Assays (ELISAs) 
Cytokine secretion in the collected supernatants (Section 3.3.4) was measured by sandwich 
ELISA, as previously described [233]. For antibody titres, blood was collected in serum 
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separator tubes (BD Bioscience, San Diego, CA) and serum was separated by centrifugation at 
8 000 rpm for 10 min at 4ºC. Titres of SEA-specific IgG1, IgG2a, IgG2b, as well as total IgE 
were determined as previously described [233].  
3.3.7 Hydroxyproline assay 
Hydroxyproline (OH) content was quantified using a modified protocol [350]. Briefly, weighed 
liver samples were hydrolysed in 6N HCl and 40mg Dowex/Norit mixture was added. The 
samples were filtered using Whatmann no. 1 filter paper, neutralised with 1% phenolphthalein 
and titrated with 10M NaOH and 3N HCl. An aliquot was mixed with isopropanol and 
chloramine-T/citrate buffer solution (pH 6.5) was added. Erlich’s reagent was added and the 
absorbance was read at 570 nm. OH levels were determined using 4-hydroxy-L-proline as a 
standard, and the data was expressed as μmoles (μM) OH per weight of tissue that contained 
104 eggs.  
3.3.8 Histology 
Liver and gut samples were fixed in 4% (v/v) formaldehyde in phosphate buffered saline (PBS), 
embedded in wax, and then processed. Sections (5-7 μm) were cut and stained with 
hematoxylin and eosin (H&E), periodic acid-Schiff reagent (PAS), and chromotrop analine 
blue solution (CAB) counterstained with Wegert’s hematoxylin for collagen staining [136]. All 
the digital images were captured on the Nikon Eclipse 90i DS-Ri2. Liver granuloma diameters 
were calculated with NIS elements Basic Research software. An average of 20 granulomas per 
mouse (6 mice per group) was included in the analysis. The number of mucus-producing goblet 
cells were quantified with Image J software (https://imagej.nih.gov/ij/).  
3.3.9 Statistics 
Statistical analysis was performed using GraphPad Prism 5 software (http://www.prism-
software.com). The data was calculated as mean ± SEM. Statistical significance was 
determined using the unpaired Student’s t test or 2-way ANOVA with Bonferroni’s post-test 
(unless otherwise stated), defining differences to IL-4Rα-/lox as significant (*,p≤0.05; 
**,p≤0.01; ***,p≤0.001).  
3.4 Results 
3.4.1 KRT14creIL-4Rα-/lox mice infected with S. mansoni show survival kinetics and weight 
loss similar to littermate control 
IL-4 and IL-13 signalling is essential for host protection against S. mansoni [130, 265, 266, 
270, 351]. Given the ability of keratinocytes to signal IL-4 [53, 239], and the ability of cercariae 
to induce cytokine secretion by keratinocytes [278, 279], we sought to investigate if IL-4/IL-
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13 signalling through IL-4Rα on keratinocytes would play a role in immunity during 
schistosomiasis. To determine whether IL-4Rα-responsive keratinocytes are required for host 
survival during acute schistosomiasis, IL-4Rα-/lox (littermate control), KRT14creIL-4Rα-/lox and 
IL-4Rα-/- mice were percutaneously infected with 80 live S. mansoni cercariae and disease 
outcome was monitored for 12 weeks. As expected, IL-4Rα-/- mice quickly succumbed to 
infection and all the mice were dead by 7 weeks post-infection (Figure 3.1 A). Conversely, 
only 20% of KRT14creIL-4Rα-/lox mice had died at 7 week post-infection, similarly to IL-4Rα-
/lox BALB/c littermate control mice (Figure 3.1 A). However, both KRT14creIL-4Rα-/lox mice 
and littermate control mice progressively succumbed to infection until 12 weeks post-infection, 
at which point all mice were dead (Figure 3.1A). We observed significant wasting in IL-4Rα-/- 
mice as indicated by severe body weight loss beginning at 5 weeks post-infection (Figure 3.1 
B). No appreciable weight loss was observed in KRT14creIL-4Rα-/lox and littermate control 
mice (Figure 3.1 B). Therefore, these data indicated that IL-4Rα-responsive keratinocytes do 
not play a role in host protection during acute schistosomiasis in mice. 
 
Figure 3.1: IL-4Rα responsive keratinocytes are not required for protection against acute 




mice were percutaneously 
infected with 80 live S. mansoni cercariae. (A) Survival kinetics of infected mice monitored over a 12 
weeks period. (B) Percent weight loss monitored on a weekly basis. Data are representative of two 
independent experiments (n = 4-6). Survival curves were compared using Log rank test. **p< 0.01 
versus IL-4Rα-/lox littermate control mice. IL-4Rα-/-
 
mice served as a positive control. 
 
3.4.2 Abrogation of IL-4Rα signalling on keratinocytes alters pathology in the liver but 
not in the gut during acute S. mansoni disease 
A strong Th2 immune response and granuloma formation occurs in response to S. mansoni 
eggs [134, 265, 266]. In order to investigate the contribution of IL-4/IL-13 responsive 
keratinocytes on the control of liver and gut pathology, we infected mice with 100 S. mansoni 
cercariae, killed mice at 7 week post-infection (experimental endpoint) and harvested liver and 
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small intestines for histological examination. We found reduced granuloma sizes in 
KRT14creIL-4Rα-/lox mice compared to IL-4Rα-/lox littermate control mice (Figure 3.2 A & D). 
As expected, IL-4Rα-/- mice had significantly smaller granulomas around the eggs compared 
to the other strains of mice (Figure 3.2 A). Hydroxyproline content provides a measure of 
collagen production and is indicative of fibrosis [350]. KRT14creIL-4Rα-/lox mice and IL-4Rα-
/lox mice had comparable hydroxyproline content while IL-4Rα-/- mice had reduced 
hydroxyproline concentration in the liver (Figure 3.2 B, D). All mutant strains had comparable 
egg numbers in the liver (Figure 3.2 C & D), indicating that the fitness of the adult worms to 
lay eggs was not compromised. Mice that quickly succumb to acute schistosomiasis have been 
shown to suffer from severe gut pathology accompanied by endotoxemia [134]. We 
investigated whether abrogation of IL-4Rα signalling on keratinocytes would impact gut 
pathology in mice infected with S. mansoni. Analysis of H&E stained gut sections showed 
unaltered gut pathology in all mutant mice (Figure 3.3). However, we observed an increased 
cellular infiltration in the gut of IL-4Rα-/- compared to the other strains (Figure 3.3). Lastly, we 
found comparable numbers of mucus producing goblet cells in both KRT14creIL-4Rα-/lox mice 
and IL-4Rα-/lox mice, while IL-4Rα-/- had reduced number of goblet cells as depicted by 
quantification of PAS stained cells in the gut (Figure 3.3 A & B). Together, this data shows 
that in KRT14creIL-4Rα-/lox mice, liver granulomas are smaller in comparison to littermate 













Figure 3.2 Reduced granuloma sizes in KRT14creIL-4Rα-/lox mice during acute schistosomiasis. IL-
4Rα-/lox, KRT14creIL-4Rα-/lox and IL-4Rα-/- mice were percutaneously infected with 100 live S. mansoni 
cercariae and analysed at 7 weeks post-infection. (A) Granuloma area surrounding eggs quantified by 
microscopic analysis on H&E stained sections. 20 granulomas per mouse were included in the analysis. 
(B) Liver fibrosis measured as hydroxyproline normalised to egg numbers. (C) Egg numbers normalised 
to tissue weight (D) Formalin-fixed liver sections (100x) stained with H&E for morphological analysis, 
and CAB for collagen content. Data is representative of 2 independent experiments. n= 4-6 mice. ***p< 






Figure 3.3 Gut pathology of KRT14creIL-4Rα-/lox is unaffected during acute schistosomiasis in 
mice. KRT14creIL-4Rα-/lox, IL-4Rα-/lox and IL-4Rα-/- mice were percutaneously infected with 100 live S. 
mansoni cercariae and analysed 7 weeks post infection. (A) Formalin-fixed liver sections (100x) stained 
with H&E for morphological analysis and  PAS to visualize mucus producing goblet cells. (B) 
Number of mucus-producing goblet cells present in the small intestine as depicted in the the 
representative image. Data is representative of 2 independent experiments. n= 4-6 mice.  
3.4.3 Spleen and liver weights of KRT14creIL-4Rα-/lox mice are characteristic of 
schistosomiasis 
To analyse gross liver and spleen pathology, we determined tissue weight after the organs were 
harvested from infected mice. We found no significant differences in both the liver and spleen 
weights of KRT14creIL-4Rα-/lox mice and IL-4Rα-/lox littermate control mice (Figure 3.4 A 
&B). Conversely, infected IL-4Rα-/- mice showed a significant reduction in spleen and liver 
weights (Figure 3.4A & B), indicating severe multiple organ defects [134]. Taken together, 
these data suggests that in KRT14creIL-4Rα-/lox mice, spleen and liver organs become enlarged 






Figure 3.4 Organ weights of KRT14creIL-4Rα-/lox  are unchanged during acute schistosomiasis. IL-
4Rα-/lox, KRT14creIL-4Rα-/lox and IL-4Rα-/- mice were percutaneously infected with 100 live S. mansoni 
cercariae and analysed at 7 weeks post-infection. (A) Spleen weight measured during autopsy. (B) Liver 
weight measured during autopsy. Data is representative of 2 independent experiments. n= 4-6 mice. 
*p< 0.05, **p< 0.01 vs IL-4Rα-/lox. 
 
3.4.4 Unaltered schistosoma-specific cellular response in infected KRT14creIL-4Rα-/lox 
mice 
Th2 immune responses is essential for host protective responses during acute schistosomiasis 
[134, 264-266]. To determine whether Schistosoma-specific cellular responses were altered in 
KRT14creIL-4Rα-/lox mice, we analysed antigen-specific cytokine responses from mesenteric 
lymph node (MLN) cells during acute schistosomiasis at 7 weeks post infection (Figure 3.5 A). 
The abrogation of IL-4Rα expression on keratinocytes did not impair the production of Th2 
cytokines (IL-4, IL-5, IL-10 and IL-13) by total MLN cells after stimulation with SEA, 
similarly to littermate control mice (Figure 3.5 A). The quantity of Th2 cytokines were 
significantly reduced in IL-4Rα-/- mice compared to littermate control mice (Figure 3.5 A).   In 
contrast, stimulation of total MLN cells from IL-4Rα-/- mice with SEA resulted in increased 
IFN-γ production, indicting a shift towards a Th1 immune response (Figure 3.5 A). Mitogenic 
α-CD3 restimulation of MLN cells from KRT14creIL-4Rα-/lox mice revealed significantly 
reduced IL-4 production when compared to littermate control mice (Figure 3.5 B). Quantities 
of IL-5; IL-6; IL-10; IL-13; IFN-γ and IL-17 in KRT14creIL-4Rα-/lox mice were similar to 
littermate control (Figure 3.5 B). IL-4Rα-/- mice had significantly less IL-4, IL-5 and IL-10. In 
addition, IL-4Rα-/- mice seemed to have a higher Th1 to Th2 cytokine ratio in comparison to 
littermate controls (Figure 3.5 B).   
To analyse the impact of IL-4Rα deficiency on keratinocyte on the differentiation and cytokine 
production by CD4+ T cells during S. mansoni infection, single cell suspensions were prepared 
from draining MLN and stained for flow cytometry analysis (Figure 3.5 C & D). There was no 
significant difference in the percentages of CD3+CD4+ T helper cells, effector, and central 
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memory T cells present in the MLN of KRT14creIL-4Rα-/lox mice compared to littermate control 
(Figure 3.5 C). In contrast, IL-4Rα-/- mice displayed significantly increased proportions of 
CD3+CD4+ T helper, and central memory T cells while the proportion of effector memory was 
reduced compared to littermate control mice (Figure 3.5 C). Analysis of intracellular cytokine 
production by CD4+ T cells restimulated with PMA/Ionomycin ex vivo revealed that MLN cells 
from KRT14creIL-4Rα-/lox mice were competent at secreting Th2 cytokines similarly to 
littermate control mice (Figure 3.5 D). In contrast, we found significantly reduced secretion of 
both Th1 and Th2 cytokines by cells from IL-4Rα-/- mice as indicated by reduced concentration 
of IFN-γ, IL-4, IL-13 and IL-10 (Figure 3.5 D). Together these data demonstrate that IL-4Rα- 
responsive keratinocytes are not required for the development of Th2 cellular responses during 
















mice were percutaneously infected with 100 live S. mansoni 
cercariae and analysed 7 weeks post-infection. (A-B) Cytokine production by mesenteric lymph node 
cells restimulated with either SEA or α-CD3. Single cell suspension was prepared from draining 
mesenteric lymph node (MLN) and cells were stained for flow cytometric analysis. (C) Recruitment of 
T helper cells (CD3+CD4+), effector T cells (CD3+CD4+CD44hiCD62Lhi), and central memory T cells 
(CD3+CD4+CD44hiCD62Lhi) into the secondary lymphoid tissue. (D) Intracellular cytokine detection 
after restimulation of MLN cells with 25 ng/ml PMA and 1 μg/ml ionomycin in vitro. Data are 
representative of two independent experiments (n = 4-6). Statistical analysis was performed with 
comparisons to the control IL-4Rα-/lox littermate mice group, as significant (*, p˂0.05, **, p˂0.01; ***, 
p˂0.001). IL-4Rα-/-
 
mice served as a positive control. 
 
 
3.4.5 Schsitosoma-specific humoral responses in infected KRT14creIL-4Rα-/lox mice 
remained unchanged  
B cell responses contribute to the development of a Th2 response during to S. mansoni infection 
[352, 353]. We assessed the impact of IL-4Rα deficiency on keratinocytes on antibody 
production, by measuring type 1 and 2 antibodies in the serum of infected mice at 7 weeks post 
infection (Figure 3.6 A-D). KRT14creIL-4Rα-/lox mice had similar titers of both type 1 and 2 
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antibodies similar to littermate controls (Figure 3.6 A-D). Conversely, global IL-4Rα-/- mice 
had significantly higher titres of type 1 isotypes IgG2a (Figure 3.6 A & B) and significantly 
lower titres of type 2 isotypes compared to littermate control mice (Figure 3.6 C & D). The 
frequencies of CD19+B220+ B cells, B220+CD21+CD23+ follicular B cells and B220+CD21+CD23- 
marginal zone B cells infiltrating the MLN in infected KRT14creIL-4Rα-/lox mice was similar to 
littermate controls (Figure 3.6 E). Conversely, infected IL-4Rα-/- mice demonstrated reduced 
proportions B cells and follicular B cells, and increased marginal zone B cells compared to 
control mice (Figure 3.6 E). The production of cytokines by B cells were not altered in 
KRT14creIL-4Rα-/lox mice similar to littermate control. This was seen in the frequency of IFN-
γ and IL-10, as well as similarly higher frequencies of IL-4 and IL-13 (Figure 3.6 F). In 
contrast, global IL-4Rα-/- mice had significant reduced Th1 and Th2 cytokines secreted by B 




Figure 3.6 Antibody production and lymph node cell B cell-cytokine production in keratinocyte-





percutaneously infected with 100 live S. mansoni cercariae and analysed at 7 weeks post-infection. (A-
D) SEA specific IgG2a, IgG2b, IgG and total IgE titers were detected in serum by ELISA. Single cell 
suspensions were prepared from the mesenteric lymph nodes and stained for flow cytometry: (E) 
recruitment of B cells (CD19+B220+); (F) follicular B cells (FO, B220+CD21+CD23+), and (G) marginal 
zone B cells (MZ, B220+CD21+CD23-) into the secondary lymphoid tissue. (H) Histogram showing the 
expression of activation marker MHCII by B cells. (I) Analysis of intracellular cytokine production by 
CD19+ B cells after restimulation of total MLN cells with 25 ng/ml PMA and 1 μg/ml ionomycin in 
vitro. Data is representative of two experiments (n=4-6). Statistical analysis was performed with 





Keratinocytes are the major contributors to the cell population of the skin epidermis [39]. While 
their involvement in wound healing and dermatitis has been extensively investigated [47, 51, 
54, 61, 349, 354, 355], their involvement  in immunity in response to infectious disease is still 
poorly understood [356]. Effective penetration of S. mansoni larval stage cercariae through the 
skin is important to establish infection. Early studies focusing on IL-7 production after S. 
mansoni infection found that keratinocytes were a major source of this cytokine, which 
contributed to the immune response [278]. Keratinocytes are capable of secreting IL-4 and IL-
13, and express the IL-4 receptor mRNA and protein [62, 63, 356]. Furthermore, studies from 
our laboratory have illustrated the importance of IL-4 and IL-4Rα in the development of host 
protective immune responses during acute schistosomiasis in mice [130, 134, 136, 357]. 
However, no studies have been carried out to determine the contribution of IL-4/IL-13 
signalling through IL-4Rα on keratinocytes in the immune response to acute schistosomiasis. 
We questioned whether abrogation of IL-4Rα expression on keratinocytes would affect the 
development of an immune response and alter the outcome of S. mansoni infection. To address 
this question, our laboratory generated a keratinocyte-specific IL-4Rα knock-out mouse model 
(KRT14creIL-4Rα-/lox) on a BALB/c genetic background using the Cre/loxP system under 
control of the KRT14 locus. We found that IL-4Rα-responsive keratinocytes are necessary for 
efficient formation of granuloma structures but are not required for protection during acute 
schistosomiasis in mice. 
A depletion of Th2 responses aggravates tissue damage and increases mortality of the host due 
to increased pro-inflammatory Th1-type responses [268, 269], as expected in global IL-4Rα-/- 
mice, that succumbed to S. mansoni at 7 weeks post-infection [136]. KRT14creIL-4Rα-/lox mice 
developed sufficient Th2 responses to survive up 7 weeks post-infection, and similar to 
littermate controls, slowly succumbed to infection. This indicated that IL-4/IL-13 signalling 
through IL-4Rα on the keratinocytes were not contributing to host protection during chronic 
schistosomiasis infection. Wolowczuk et al. investigated the cytokine profiles of the skin from 
mice after S. mansoni infection [358]. He detected a maximum quantity of IL-4 at 5 days post 
infection, but by day 7, this cytokine was undetectable [358]. This early IL-4 could be crucial 
for educating and priming Th2 immunity that could be required later on for host protection. 
The presence of the eggs retained within the liver and gut wall causes a Th2-driven response 
with granuloma formation, which ultimately causes morbidity and mortality in mice and 
humans [134, 265, 266, 359]. In accordance with this, IL-4Rα-/- mice displayed impaired 
granuloma formation [134, 275]. KRT14creIL-4Rα-/lox mice had smaller granulomas in 
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comparison to the littermate controls. This indicates that while these mice mounted a sufficient 
Th2 immune response for survival, the response was not optimal for efficient granuloma 
formation. By blocking the IL-4Rα chain, we not only halt signalling of IL-4 through this 
receptor, but in addition, IL-13 is prevented from signalling through the IL-4Rα too. Perhaps 
this decrease in IL-13, also plays some role in the immune response as IL-13 is involved in the 
mediation of fibrosis in the liver [276, 360]. Further testing for an indication of hepatocellular 
damage in these mice by serum measurement of aspartate aminotransferase (AST) could be 
performed [134]. 
During S. mansoni infection, highly susceptible mice demonstrate increased inflammation of 
the gut, in addition to endotoxemia and septic shock [134, 265, 275]. In agreement with this, 
IL-4Rα-/- mice demonstrated increased gut inflammation in comparison to littermate control 
mice. Similar to the littermate control mice, KRT14creIL-4Rα-/lox mice did not show 
inflammation in the gut, and did not illustrate goblet cell hyperplasia as seen by PAS staining. 
This suggests that the mice are still able to control gut inflammation and maintain regulatory 
responses. We did not investigate endotoxemia and septic shock in these mice, but this may be 
examined by measuring the lipopolysaccharide (LPS) in the serum [130, 134, 136]. Herbert et 
al. demonstrated that IL-4Rα-/- mice suffer from defects in their organs, as indicated by severe 
atrophy of the spleen and liver during acute schistosomiasis [134, 361], supporting our 
observations in IL-4Rα-/- mice in this study. Conversely, KRT14creIL-4Rα-/lox mice 
demonstrated spleen and liver weights similar to littermate controls, with both mouse groups 
having exhibited severe splenomegaly, characteristic of Schistosoma infection [362, 363]. 
The development of a polarised Th2 immune response is essential for survival of the host 
during S. mansoni infection [265, 268-270]. Schistosoma-egg antigen (SEA) restimulation of 
MLN cells from KRT14creIL-4Rα-/lox mice, for cytokine production by total lymph node cell 
populations, demonstrated a similar response to littermate control mice, both showing a greater 
Th2 cytokine production. Mitogenic restimulation of MLN cells from KRT14creIL-4Rα-/lox 
mice demonstrated a similar trend, with the exception of significantly reduced production of 
IL-4 compared to littermate controls.  The production of IL-4 by CD4+ T helper cells, however, 
as determined by intracellular staining, was not downregulated, and illustrated a trend of higher 
Th2 cytokine production. In agreement with previously published studies, IL-4Rα-/- mice 
demonstrated a shift towards a Th1 immune response, evident in significantly upregulated IFN-
γ production after MLN restimulation, and downregulation of Th2 cytokines IL-4, IL-13, IL-
5, IL-6 and IL-10 [310]. Differentiation and activation of CD4+ T helper cells was unaffected 
by the absence of IL-4Rα-responsive keratinocytes in KRT14creIL-4Rα-/lox mice, similar to 
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littermate control mice. In contrast, IL-4Rα-/- mice showed significantly reduced effector 
memory function as previously demonstrated [364], and significantly increased CD4+ T helper 
functions, and memory T cell responses. Contradictory to our findings, Ndlovu et al. [364] 
demonstrated significantly lower CD4+ T helper responses in  IL-4Rα-/- mice during S. mansoni 
infections. Despite this difference, these mice behaved in the same manner during acute 
schistosomiasis. 
During S. mansoni infection, alternatively activated macrophages are recruited to regulate and 
decrease organ damage that is caused by the trapped eggs [134]. Staining for inducible nitric 
oxide synthase (for classically activated macrophages) and arginase (for alternatively activated 
macrophages) could be performed and quantified, to provide an indication of the ratio of 
classically activated macrophages to alternatively activated macrophages present in 
KRT14creIL-4Rα-/lox mice.  
The B cell and antibody responses contribute to Th2 and immune regulatory responses during 
S. mansoni infection [243, 274]. Antibody responses in KRT14creIL-4Rα-/lox mice demonstrated 
a predominant type 2 antibody response characterised by the increased production of SEA-
specific IgG1 and total IgE, similar to littermate control mice. This indicates that signalling of 
IL-4 through the IL-4Rα on keratinocytes, is not essential in developing sufficient type 2 
antibody responses to modulate the immune response. This also indicates that these mice can 
efficiently undergo antibody isotype switching. Conversely, IL-4Rα-/- mice were seen to have 
a  predominant type 1 antibody response, observed by the increase in production of IgG2a and 
IgG2b, as expected, and previously described [130, 134, 364]. This finding relates to the role 
IL-4 plays in isotype switching for the production of type 2 antibodies by B cells [292, 322, 
365]. B cell differentiation in KRT14creIL-4Rα-/lox was unchanged, and similar to littermate 
control mice, confirming these mice can carry out B cell differentiation as normal. In 
accordance with previous data, IL-4Rα-/- mice had significantly decreased follicular B cells and 
significantly increased marginal zone B cells, in comparison to the littermate control mice 
[364]. B cell activation not altered in in KRT14creIL-4Rα-/lox mice, similar to littermate controls, 
while IL-4Rα-/- mice showed a slight decrease as expected [364]. Helminth studies have 
indicated that B cells can promote Th2 responses, in addition to regulating Th1 responses [352, 
366, 367]. Our data suggests that in KRT14creIL-4Rα-/lox mice, B cells are still capable of 
contributing to the Th2 response, and still has immunomodulatory function.  While 
KRT14creIL-4Rα-/lox mice showed B cell cytokine production to be a mixed Th1/Th2 response, 
there did appear to be higher levels of Th2 IL-4, IL-13 in comparison to Th1 IFN-γ. The 
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cytokines secreted by B cells contribute to Th effector functions and memory Th development 
[368-371]. Given that in KRT14creIL-4Rα-/lox mice, effector and memory Th responses were 
unchanged, it suggests that sufficient cytokine production by B cells occurs in these mice, 
independent of IL-4/IL-13 signalling through IL-4Rα on keratinocytes. As expected, global IL-
4Rα-/- mice showed significantly decreased Th1 and Th2 B cell cytokines [364]. Together, 
these findings indicate that IL-4/IL-13 signalling through the IL-4Rα on keratinocytes is not 
important for the development or differentiation of B cells, or the production of cytokines by 
these B cells, during S. mansoni infection.  
3.6 Conclusion  
The findings in this study indicate that KRT14creIL-4Rα-/lox mice have a similar mortality rate 
compared to littermate controls during acute S. mansoni infection. In KRT14creIL-4Rα-/lox mice, 
liver granulomas were smaller than those in littermate controls, however, gut pathology 
appeared to be similar. Normal hepatosplenomegaly occurred in KRT14creIL-4Rα-/lox mice, 
similar to littermate control mice. Finally, the Th2 cellular responses, and type 2 antibody 
responses in KRT14creIL-4Rα-/lox mice were similar to littermate control mice. In the absence 
of IL-4Rα-responsive keratinocytes, KRT14creIL-4Rα-/lox mice can still elicit a sufficient Th2 
response for protection during S. mansoni infection. Collectively, our findings indicate that IL-
4/IL-13 signalling through the IL-4Rα signalling on keratinocytes is not required for protection 
during acute S. mansoni infection in mice, but does contribute to the optimal formation of Th2 









Chapter 4: General Discussion and conclusions 
4.1 Aim 
The aim of this thesis was to investigate the role of IL-4/IL-13 signalling through IL-4Rα on 
keratinocytes during cutaneous leishmaniasis and acute schistosomiasis. To perform this 
investigation, our laboratory generated a keratinocyte cell specific-IL-4Rα knock-out mouse 
(KRT14creIL-4Rα-/lox) on both BALB/c and C57BL/6 genetic backgrounds, using gene 
targeting and site-specific recombination (cre/loxP) under control of the KRT14 promoter. 
4.2 Summary of results from Chapter 2 
Our work on cutaneous leishmaniasis was presented in Chapter 2. Following footpad infection 
of KRT14creIL-4Rα-/lox BALB/c mice with L. major IL-81 and LV39, we found these mice to 
remain susceptible to infection, similar to littermate controls. They developed swelling and 
disease progression, had high parasite burdens, and developed cellular and humoral immunity 
similar to littermate controls. KRT14creIL-4Rα-/lox C57BL/6 mice infected with L. major in the 
footpad remained resistant to L. major infection similar to littermate controls (C57BL/6 genetic 
background) and C57BL/6 mice. Collectively, our findings indicated that the deletion of the 
IL-4Rα on keratinocytes in BALB/c and C57BL/6 mice did not influence the outcome of 
disease during L. major infection in the footpad model. In the ear infection model, KRT14creIL-
4Rα-/lox BALB/c mice infected with L. major, developed swelling and disease progression and 
had high parasite burdens, similar to littermate controls. We did, however, notice that the 
parasite burden of KRT14creIL-4Rα-/lox BALB/c mice in the ear was significantly lower to 
littermate control mice, only during infection with L. major LV39. The production of Th1 IFN-
γ, Th2 IL-4 and IL-13, type 1 IgG2a and IgG2b, and type 2 IgG1 and total IgE were comparable 
in KRT14creIL-4Rα-/lox BALB/c and littermate control mice. KRT14creIL-4Rα-/lox C57BL/6 
mice infected in the ear with L. major had decreased swelling and parasite burdens, and 
developed cellular and humoral similar to littermate control (on C57BL/6 genetic background) 
and C57BL/6 mice. Together, these results indicated once more, that IL-4Rα-responsive 
keratinocytes do not contribute to the outcome of disease during L. major infection in the ear 
model. From this, we can infer that the IL-4/IL-13, which both signal through the IL-4Rα on 
keratinocytes, are not required for control of infection during cutaneous leishmaniasis. 
Additionally, on a BALB/c background, the lack of IL-4Rα-responsive keratinocytes allows 
these mice to better control the replication of parasites at the site of infection compared to 
littermate control, indicating that the IL-4/IL-13 signalling through the IL-4Rα on keratinocytes 
appeared to contributed to susceptibility in these mice.  
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4.3 Studies contributing to the generation of the hypothesis in Chapter 2 
Our work followed on from two pivotal studies on L. major by Biedermann et al. [235] and 
Ehrchen et al. [239] that are extensively described in Chapter 2 of this thesis. Briefly, 
Biedermann et al. illustrated the “IL-4 instruction theory” showing that recombinant IL-4 
administered exogenously can instruct dendritic cells to secrete IL-12 to drive a T helper 1 
(Th1) polarised immune response [235]. This was demonstrated with in vitro and in vivo mouse 
experiments. They also found that a push towards a Th1 immune response required IL-4 that 
was present at the early stages of infection. The findings presented by Biedermann et al. [235] 
were also recently supported by work carried out in our laboratory by Hurdayal et al. [135] 
who provided a better indication of the contribution of biological quantities of endogenous IL-
4 to drive dendritic cells to elicit a polarised Th1 immune response. Here, the authors carried 
out L. major infections on genetically modified BALB/c mice, having abrogated IL-4 receptor 
alpha (IL-4Rα) on dendritic cells. Their findings indicated that IL-4-mediated instruction of 
dendritic cells occurs in vivo with biological quantities of IL-4 acting on IL-4Rα-responsive 
dendritic cells to promote survival of the host [135], and further supported the findings reported 
by Biedermann et al. [235]. Working on the theory that early IL-4 is vital in driving dendritic 
cells to induce a Th1 immune response, Ehrchen et al. directed the focus to the early stages of 
infection, and investigated the initial infected site, the microenvironment of the infected tissue 
[239]. They found that keratinocytes are rapidly induced to secrete immunomodulatory 
mediators IL-12, IL-1β, and IL-4, in the presence of L. major promastigotes, and Th2 cytokine 
IL-4 from keratinocytes appeared to be the significantly highly present in genetically resistant 
C57BL/6 mice. Additionally, early local neutralization of the IL-4 in these resistant mice 
resulted in a Th2 switch, making these mice susceptible to L. major infection [239]. These 
finding suggested a possible role for keratinocytes in contributing to Th1 immunity during 
experimental leishmaniasis. Collectively, the data and observations from Biedermann et al. 
[235] and Ehrchen et al. [239] support a possible role for keratinocyte-derived-IL-4 immunity 
against Leishmania. From these studies, we constructed a hypothesis: if early IL-4 instructing 
dendritic cells is derived from keratinocytes, and we deleted the IL-4Rα signalling receptor 
through which IL-4 signals on these cells, then IL-4 will not be able to signal in this manner, 
and dendritic cells would not be able to promote a Th1 response. While Ehrchen et al. did not 
find IL-13 to be significant during his study [239], we could not exclude IL-13, as this cytokine 
can signal through the IL-4Rα signalling receptor on keratinocytes [67]. 
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4.4 Considerations (L. major study) 
The footpad infection model for leishmaniasis is well established in our laboratory [132, 135, 
294] and in other groups [285-287]. Furthermore, both Biedermann et al. [235] and Ehrchen et 
al. [239] used this model for their experiments. For these reasons, we performed experiments 
using this model. When we found no significant findings using the footpad infection model, 
we decided to test our hypothesis using the ear infection model. The ear infection model 
involves an intradermal inoculation of low dose metacyclic promastigote L. major parasites in 
the ear, a site of infection that is becoming more favoured, as it better mimics natural infection 
by the sandfly, and is better at reproducing the natural lesion formed [281-283, 326-329]. In 
addition to these reasons, considering we did find a significant reduction of parasite burden in 
the ear of infected KRT14creIL-4Rα-/lox BALB/c mice, this model may in fact be a better choice 
for L. major infections. 
Further experiments could be performed to strengthen our findings. As Ehrchen et al. looked 
at the skin after infection with L. major [239], we could perform similar experiments to further 
investigate the site of infection, in both the footpad and ear model. Here we could observe 
cellular infiltration by extracellular staining on the skin, and skin-draining lymph nodes to look 
at other cells that may be contributing to the immune response or control of infection. 
Furthermore, the question of the source of early IL-4 driving dendritic cells to develop a 
polarised Th1 response has yet to be determined. To address this, neutrophils and mast cells 
could be explored further, as described in Chapter 2. These cells can signal IL-4/IL-13 through 
IL-4Rα, and are two of the first cells to make contact with the Leishmania parasites after 
infection [183-185, 331, 334, 339, 341]. Additionally, eosinophils and basophils could be 
investigated [372]. During L. major and L. amazonenesis infection, eosinophils are recruited 
to the site of infection [373, 374]. Furthermore, eosinophils have been suggested to contribute 
to parasite clearance at the site of infection, during the initial hours of L. mexicana infection 
[375]. In humans, basophils are a key source of IL-4, which contributes to pathogenesis during 
allergic inflammation [376, 377] These cells are also an important source of IL-13 [372, 376, 
378]. It would be interesting to determine if these cells contribute to L. major infection. 
Histological analysis of the infected footpad or ear could be performed to observe the sites of 
infection, and changes in epithelial structure. Our intracellular staining panels could also 
include markers to indicate the presence and proportions of classically and alternatively 
activated macrophages in our KRT14creIL-4Rα-/lox. Additionally, we need to consider, that if 
IL-13 is playing a role during L. major infection, this cytokine can signal not only through the 
IL-4Rα on keratinocytes, but also through the IL-13R on these cells.  
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4.5 Conclusions to L. major study 
Overall, we showed that IL-4Rα signalling on keratinocytes does not drive a Th1 immune 
response and is not important for control during L. major infection. From this, we infer that IL-
4/IL-13 signalling through the IL-4Rα receptor on keratinocytes also does not influence the 
immune response, and does not drive Th1 immunity as suggested. We demonstrated this using 
the footpad and ear models for L. major. Our findings also highlight the importance of noting 
the difference in source and sub strain of L. major parasite during experiments, as this 
difference can alter the immune response differently. Finally, we have provided the first report 
on the immune responses in global IL-4Rα-/- on the C57BL/6 genetic background during L. 
major infection in mice.   
4.6 Chapter 3: Hypothesis, summary and conclusions from S. mansoni study 
Schistosomiasis is a Th2 controlled disease, while leishmaniasis is Th1 controlled, and while 
IL-4Rα is important for host protection during acute schistosomiasis as shown with mouse 
models [130, 134, 136, 277], IL-4Rα plays a role in susceptibility to leishmansiasis as 
previously explained. The skin is involved in the life cycle of the Schistosoma parasite, as 
explained in Chapter 1, and the epidermal layer is abundant in keratinocytes. Furthermore, it 
has been shown S. mansoni cercariae can influence keratinocytes to secrete IL-7 in response to 
S. mansoni infection [278, 279]. Keeping these facts in mind, we hypothesised that IL-4Rα-
responsive keratinocytes would play a role in protection during S. mansoni infection. We tested 
this hypothesis using the KRT14creIL-4Rα-/lox BALB/c mouse. After the mice were 
percutaneously infected with S. mansoni cercariae, we monitored disease progression and 
evaluated their immune response. Mortality studies indicated that IL-4Rα-responsive 
keratinocytes did not appear to increase protection in these mice during chronic S. mansoni 
infection, as they behaved similar to littermate control mice, indicated by survival and weight 
loss. The development of a polarised Th2 immune response is required for the hosts’ survival 
during S. mansoni [265, 268-270]. The production of T helper cytokines in KRT14creIL-4Rα-
/lox BALB/c mice appeared to be Th2 polarised and was similar to littermate control mice. 
During S. mansoni infection, immunomodulation is necessary for protection, and mechanisms 
include B cell and antibody responses [243, 274]. KRT14creIL-4Rα-/lox mice demonstrated a 
predominant type 2 antibody response as seen by the increased production of IgG1 and total 
IgE, similar to littermate control mice. We noted that in these KRT14creIL-4Rα-/lox BALB/c 
mice, the areas of the granulomas were significantly less compared to littermate control mice, 
suggesting a role for IL-4Rα-responsive keratinocytes in granuloma formation. Overall, IL-
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4/IL-13 signalling the IL-4Rα on keratinocytes does not appear to be important in the control 
of disease during S. mansoni infection.  
4.7 Considerations (S. mansoni study) 
As with the Leishmania study, the role of IL-13 should be considered, both IL-4Rα-dependent 
and IL-13R dependent, as IL-13 does contribute to Th2 immunity during schistosomiasis. 
Additional experiment could be performed to supplement our findings. It would be interesting 
to also investigate the infection site (the abdominal skin where the cercariae penetrate), and the 
skin-draining lymph nodes of KRT14creIL-4Rα-/lox mice shortly after infection, implementing 
histological staining, extracellular staining for cell population, and cytokine assays. This can 
illustrate any early effects of the deletion of IL-4Rα-responsive keratinocytes during acute 
schistosomiasis. Liver pathology could be investigated for the presence of classically or 
alternatively activated macrophages by the presence iNOS and Arginase, by histological 
staining of sections of the liver. To provide an indication of hepatocellular damage in 
KRT14creIL-4Rα-/lox mice, the levels of aspartate transaminase in the serum could be measured. 
Gut pathology could also be looked at further, by detection of LPS in the serum of KRT14creIL-
4Rα-/lox mice. 
4.8 Final conclusions  
IL-4/IL-13 signalling though the IL-4Rα on keratinocytes in BALB/c and C57BL/6 mice is not 
essential for control of disease during L. major infection in mice. IL-4/IL-13 signalling though 
the IL-4Rα on keratinocytes in BALB/c mice contribute to granuloma formation, but are not 
required for the control of acute schistosomiasis.  
4.9 Relevance of the studies 
Neglected tropical diseases (NTD) occur in 149 countries worldwide, primarily in the tropical 
and subtropical regions [379]. There are currently 17 different diseases characterised as an 
NTD, including Echinococcosis, human African Trypanosomiasis, leishmaniasis, and 
schistosomiasis [379, 380]. Factors contributing to spread of these diseases include poverty, 
inadequate sanitation, and close proximity to infectious vectors and domestic livestock [379, 
380]. While there are control strategies that have been set in place, for many of these diseases 
control alone is not sufficient, and treatment with drugs and vaccines is crucial [379-382]. 
Furthermore, for leishmaniasis and schistosomiasis, despite numerous vaccine targets and 
trials, there has yet to be a safe and effective vaccine designed. Due to their high morbidity and 
mortality rates, cases of drug toxicity and increased drug resistance [382, 383], understanding 
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underlying mechanisms of host-parasite interactions, pathogenesis, and immune responses is 
extremely important. While some of these studies, like ours, may not may not provide drug or 
vaccine targets, they still raise important questions and ideas which could contribute in some 
way to the fight against these diseases.  
4.10 Future work: wound healing studies 
The skin is regarded the first line barrier of protection in humans and animals, and contains 
cells in the dermis and epidermis. The epidermis is stratified epithelium that contains of ten to 
twenty layers of keratinocytes. These cells make up majority of the cell population in the 
epidermis [39]. Apart from their role in barrier maintenance, keratinocytes play an important 
role in wound healing, and are essential during the epithelialization phase of this process [47]. 
Furthermore, keratinocytes are capable of producing growth factors, cytokines, and 
chemoattractants, as described in detail in Chapter 1 [53]. There are many factors that hamper 
wound healing. These factors may be regarded as either local or systemic. Local factors such 
as oxygenation, infection and foreign agents, influence the characteristics of the wound 
directly. Systemic factors such as age, gender, stress, obesity and cancer, represents the general 
health or diseased state of the individual that alters their ability to heal the wound. The 
importance of keratinocytes in skin-related diseases including atopic dermatitis and allergy has 
also been highlighted  [54, 384]. IL-4 and IL-4Rα have been shown to be involved in wound 
healing [354, 385-387]. A study of note was performed by Salmon-Ehr et al., who detected IL-
4 early at the site of a wound, and not in non-wounded controls [354]. Additionally, he showed 
accelerated wound closure in mouse wounds treated with IL-4, when compared to those treated 
with PBS controls, further implying that IL-4 is beneficial for wound-healing [354]. We 
hypothesize that IL-4/IL-13 signalling through the IL-4Rα on keratinocytes may play a role in 
wound-healing, and aim to further investigate this with a wound healing model based on the 













Supplementary Figure 1.  Characterization of KRT14creIL-4Rα-/lox mice. (A) Mouse breeding 
strategy. Transgenic BALB/c mice expressing Cre-recombinase under control of the krt14 promoter 
was inter-crossed with IL-4Rα-/- BALB/c mice and IL- 4Rαlox/lox BALB/c mice to generate LckcreIL-
4Rα-/lox mice (B) PCR analysis of KRT14creIL-4Rα-/lox on a BALB/c and C7BL/6 background indicated 
the following: KRT14cre specific gene is 494 base pairs (bp), loxP is 450 base pairs (floxed) or 356 base 
pairs (wildtype) and deleted IL-4Rα gene is 471 bp, with the wild-type (WT) IL-4Rα being 600 bp. (C-
D) Phenotypic analysis. Flow cytometry was performed to show IL-4Rα expression on isolated ear 
keratinocytes in KRT14creIL-4Rα-/lox on BALB/c (C) and C57BL/6 genetic backgrounds (D): 
KRT14creIL-4Rα-/lox (orange), global IL-4Rα-/- (red), and wildtype BALB/c mice (blue). Keratinocytes 
were gated as CD45-CD49+K14+. Inter-crossing and genotyping of mice was performed by the UCT 
Genotyping team. PCR analysis was performed by Miss M. Ansarie of the UCT Genotyping team. 
Isolation of ear keratinocytes and IL-4Rα staining was performed at the University Of Lausanne, in the 








Supplementary Figure 2.  Flow cytometry plots and gating strategies for surface staining of lymph 
node cells to illustrate T helper, T cytotoxic and B cell populations. 
 
 
Supplementary Figure 3.  Flow cytometry plots and gating strategies for surface staining of lymph 




Supplementary Figure 4.  Flow cytometry plots and gating strategies for surface staining of lymph 


































10× Phosphate buffered 
saline (PBS) 




Dissolve 1 x bottle Schneider’s Drosphilia Medium (Sigma-
Aldrich) and 0.4 g Sodium Bicarbonate in 800 ml distilled H2O. 
Adjust pH to 9.2. Stir (10 min), adjust pH to 6.7. Dissolve 0.6 g 
anhydrous calcium chloride in 50 ml water. Add slowly to 
medium. Add 20 % heat-inactivated FCS. Adjust pH to 7.0. Add 
2.5 ml 100 U/ml penicillin G and 100 μg/ml streptomycin 





Add 50 ml % FCS,  5 ml HEPES, 500 μl β-2-mercaptoethanol, 





Add 2.5 ml Pen/Strep, 50 ml FCS, to 447,5 ml IMDM (Gibco), 
adjust pH to 7.4 
FACS Buffer  Add 1  g bovine serum albumin (BSA) to 1 L 1× PBS, filter-
sterilize 
Permeabilization Buffer  
 
Add 0.5 g Saponin, 0.055 g CaCl2, 0.0625 g MgS04, 0.25 g 
NaN3, 0.5 g BSA, 5 ml 1 M HEPES to 400 ml 1× PBS. Adjust 
to pH 7.4. Make volume up to 500 ml with distilled H2O, filter-
sterilize. 




Add 1.6 g Na2CO3, 2.9 g NaHCO3, 4.2 g NaCl to 100 ml 10× 
PBS. Make volume up to 1 L with distilled H2O, adjust pH to 
9.5 
Antibody ELISA 
Coating Buffer  
Dissolve 8g BSA (Merck) in 100 ml 10× PBS. Adjust pH to 9.5, 
make volume up to 1 L in with distilled H2O,  
ELISA Dilution Buffer  
 
Dissolve 10g BSA (Roche), 0.2g NaN3 (Merck). Make  volume 
up to 1 L with 1× PBS 
ELISA Substrate 
Buffer 
Dissolve 0.2g NaN3, 97 ml di-ethanolamine, 0.8g MgCl2.6H2O 
in 700 ml distilled H2O, adjust pH to 9.8. Make volume up to 1 
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